Published in final edited form as:

J Mol Biol. 2019 July 26; 431(16): 2982–3009. doi:10.1016/j.jmb.2019.05.003.

How environmental fungi cause a range of clinical outcomes in susceptible hosts

Steven T. Denham^{*,1}, Morgan A. Wambaugh^{*,1}, Jessica C. S. Brown^{1,2}

¹Division of Microbiology and Immunology, Pathology Department, University of Utah School of Medicine, Salt Lake City, UT, USA

Introduction

Airway exposure to environmental fungi is constant, but very few are capable of establishing disease in humans. Of the ~120,000 documented fungal species and the estimated ~3 million species of fungi [1], only ~300 cause disease in humans [2]. Most of these 300 only rarely cause disease, while a dozen or so species cause the majority of fungal disease [3]. Consequences of exposure to environmental fungi varies from clearance by the host to establishment of a latent, reactivatable subclinical infection, to severe systemic disease [4–6]. Systemic fungal infections are a major cause of morbidity and mortality, killing >1.6 million people each year and costing the US healthcare system \$7.2 billion dollars annually [7]. Moreover, mortality rates for systemic fungal infections are high. For instance, mortality rates can reach 80% for cryptococcosis [8] and 90% for aspergillosis [9] in resource-limited settings.

Life-threatening infections in immunocompetent individuals have been documented for all the fungi we discuss. However, the majority of life-threatening infections typically present in individuals with particular immunocompromising risk factors [4]. Thus, the outcome of infection is determined by a constellation of fungal traits and host susceptibilities (Table 1). In this review, we discuss host and fungal factors that contribute to infectivity, persistence within the host, and progression to life-threatening infections for five groups of fungi: *Cryptococcus*, *Aspergillus*, *Histoplasma*, *Blastomyces*, and *Coccidioides* spp. These common environmental fungi do not require an infectious life cycle for their survival. They are not transmissible between humans, nor are humans considered a particularly suitable niche for commensalism, such as it is for certain *Candida* spp. [10]. We do not discuss *Candida* spp., which are addressed elsewhere in this issue.

Aspergillus spp. and *Cryptococcus* spp. are considered some of the more cosmopolitan fungal species. Due to their large geographical range, respiratory exposure to these fungi is commonplace [11]. *Aspergillus* spp. commonly cause both asymptomatic and symptomatic

²Correspondence: jessica.brown@path.utah.edu.

*These authors contributed equally.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

disease within the respiratory tract, but can also invade deeper tissues [5]. *Cryptococcus* spp. can establish latent, reactivatable infections within the lungs [12, 13] and possibly the liver [14, 15]. However, the presenting illness in those with impaired immune systems is usually central nervous system (CNS) infection and fungal meningoencephalitis [13]. *Histoplasma*, *Blastomyces*, and *Coccidioides* spp. belong to the Onygenales order of ascomycetes fungal pathogens, which also includes *Paracoccidioides*. These fungi are thermal dimorphs that undergo a reversible morphological transition from saprobic spore-forming hyphal growth at room temperature (25°C) to parasitic yeast/spherule forms at core human body temperature (37°C) [16]. Relative to *Aspergillus* and *Cryptococcus* spp., the thermal dimorphs tend to have more constrained environmental niches and geographical range. They are primary pathogens of humans, as they commonly infect immunocompetent people to produce self-limiting pneumonias [16]. However, certain immunocompromising risk factors greatly increase the potential severity of disease and extrapulmonary dissemination.

Ecology, Epidemiology, and Clinical Outcomes

Aspergillus

Aspergillus spp. are globally ubiquitous molds found in both the outdoor and indoor environments [17]. Approximately 90% of infections are caused by *A. fumigatus* [18], which is the focus of this review unless otherwise stated. Other disease-causing species include *A. flavus*, *A. niger*, and *A. terreus* [18, 19].

Aspergillus spp. are globally distributed and possess a wide range of flexible traits that facilitate survival in diverse environments. These include heat tolerance [20], cold tolerance [21], drought tolerance [22], other stress tolerance [23–25], and the ability to utilize a variety of carbon and nitrogen sources [26, 27]. While not all *Aspergillus* species, or even isolates within a species [24, 28], possess the full range of these environmental survival traits, the range of phenotypes frequently correlates with virulence potential [24]. For example, *Aspergillus* spp. that are, on average, more likely to germinate at high temperatures are more likely to cause mammalian virulence [20]. The molecular mechanisms underlying these tolerances are of great interest to the medical mycology community and we recommend that readers interested in these mechanisms start with the following reviews: [23, 25, 27, 29, 30].

Due to the global distribution of *Aspergillus* spp., preventing exposure is virtually impossible. Every time a human inhales, we are predicted to breathe in up to 10 fungal spores; this population frequently includes *Aspergillus* spp. [31]. Even though *Aspergillus* spp. exposure can occur either indoors or outdoors [32], activities such as construction and building demolition near hospital sites further increase the risk of aspergillosis in vulnerable patients, presumably due to increasing airborne conidia levels when disturbing soil [33, 34]. Municipal waste workers [35], others who work with compost material [35], and poultry farm workers [36] are at increased risk for *Aspergillus*-associated diseases.

Aspergillosis includes many forms. Invasive pulmonary aspergillosis (IPA) occurs when fungi enter the lung, invade and damage lung tissue, and enter blood vessels. Neutropenia [37] or neutrophil dysfunction [38] is the major risk factor for IPA. It will sometimes use the bloodstream to spread to distal sites, including the brain and skin [39]. Chronic pulmonary

aspergillosis (CPA) still damages lung tissue but progresses more slowly than IPA, does not invade blood vessels, and does not disseminate, although it causes extensive localized damage [40]. An aspergilloma is a localized fungal and inflammatory cell ball that grows in a pre-existing lung cavity [40] and is frequently asymptomatic [5, 40]. Allergic bronchopulmonary aspergillosis (ABPA) is caused by hypersensitivity to *Aspergillus* antigens and increases asthma severity and airflow restriction in patients with asthma [41, 42]. *Aspergillus* spp. can also colonize the lungs [43].

Aspergillosis is not necessarily progressive; patients with invasive pulmonary aspergillosis do not always start with ABPA or even chronic colonization of the lungs [39], nor does colonization invariably lead to severe clinical outcomes [44]. This is particularly the case for neutropenic patients and those undergoing bone marrow transplant, the largest risk groups for invasive pulmonary aspergillosis [19, 39]. Mortality rates vary from 50% [45] to 95% [4] depending on the speed of diagnosis, patient condition, and treatment availability.

However, a number of conditions are associated with a positive *Aspergillus* spp. sputum sample, even without symptomatic disease. These include patients with diabetes mellitus and those administered corticosteroids [19]. Patients with pulmonary disorders are at greater risk for *Aspergillus* spp. colonization and infection. A study of patients in a pulmonary ward over a decade found that <10% of patient respiratory samples contained an *Aspergillus* spp., of which 45% displayed no further symptoms of aspergillosis [46]. All of the remaining 55% had a form of pulmonary aspergillosis, from invasive pulmonary aspergillosis (IPA) (13%) to ABPA or chronic necrotizing pulmonary aspergillosis (48%) [46]. Chronic obstructive pulmonary disease (COPD) patients show an overall increase in IPA and *Aspergillus* colonization [47]. Recent work also established fungi in general and *Aspergillus* spp. in particular as part of the flora colonizing lungs of cystic fibrosis (CF) patients [48–52]. When *Aspergillus* colonization leads to ABPA, it exacerbates inflammation of CF patients' lungs and decreases in lung function [41, 42].

Cryptococcus

Cryptococcosis is an invasive mycosis that primarily affects immunocompromised individuals, though it occasionally affects otherwise healthy individuals [13]. *Cryptococcus neoformans* and *C. gattii* are basidiomycetes yeasts and the etiological agents of cryptococcosis, though most cases are attributed to *C. neoformans* [13, 53, 54]. *C. neoformans* is globally distributed in a multitude of environments, and exposure is near universal. In a New York City sample population for example, 70% of sera from children greater than 5 years old and 56% of sera from children 2–5 years old reacted with cryptococcal antigens [55]. Sera from children 1.1–2 years old had minimal activity against cryptococcal antigens [55].

Despite this high prevalence of exposure, individuals generally do not display clinical symptoms unless they are immunocompromised. Those with low CD4+ T cell counts are at exceptionally high risk; cryptococcosis accounts for 15% of AIDS related mortalities worldwide [8, 13]. There are an estimated 220,000 cases each year with 180,000 deaths globally [8]. Though the advent of highly active antiretroviral therapy (HAART) has helped

reduce annual incidence of cryptococcosis globally, disease burden remains high in regions with limited access to HAART, such as sub-Saharan Africa [8].

Cryptococcus was first identified in 1894 from a chronic granuloma of a tibial bone [53, 54, 56]. Since then more than 30 species of *Cryptococcus* have been identified, though two cause the majority of human disease: *Cryptococcus neoformans* and *Cryptococcus gattii* [13, 56]. Each species has since been divided into two serotypes for further classification [13]. *C. neoformans* var. *grubii* (serotype A) accounts for 95% of cryptococcal cases, followed by *C. neoformans* var. *neoformans* (serotype D) and *C. gattii* serotypes B and C [13, 56]. *C. neoformans* is often associated with decaying tree hollows and bird guano, particularly pigeons [13, 53, 54, 56, 57]. Though these birds are not symptomatically infected, they can harbor the fungus on their feathers and beaks and are likely an urban infection source [53, 58].

C. gattii, is not as widely distributed as *C. neoformans*. *C. gattii* is prevalent in tropical and semi-tropical regions of Australia and southeast Asia [57, 59], but can also be found in Hawaii, Brazil, and central Africa. *C. gattii* is frequently isolated from eucalyptus trees and koalas [13, 57, 60], which may serve as a reservoir in these areas. However, the Vancouver Island outbreak of the 1990s revealed *C. gattii* endemicity in more temperate climates, including the Pacific Northwest (North America) and parts of Europe [13, 61–63]. Isolates from the Pacific Northwest also exhibited increased virulence when compared to more tropical *C. gattii* strains [59, 64]. However, *C. neoformans* remains the predominant etiologic agent of disease, even in areas with endemic *C. gattii* [13, 53, 57].

Cryptococcal infections were rare prior to the AIDS pandemic, with fewer than 300 cases worldwide in the 1950s [54]. However, with increasing populations of immunocompromised individuals, *Cryptococcus* spp. have become a major threat. Upon immunological suppression, a latent or newly acquired infection spreads from the lungs to multiple body sites, including the prostate, skin, and eyes. Moreover, the fungus has a predilection for the CNS [65], and cryptococcosis more often presents as meningoencephalitis than pneumonia [13]. Though *C. neoformans* and *C. gattii* infections share a similar pathogenesis, *C. gattii* is more likely to cause symptomatic pulmonary infections and infections in individuals without obvious immunosuppression [59, 66, 67].

Cell-mediated immunity is critical for the clearance or control of *Cryptococcus*. A predominantly T helper-1 (Th1) reaction is essential for containing the infection, and when weakened may lead to fungal dissemination [13]. Due to a severe loss of CD4⁺ T cells, HIV/AIDS patients account for 80% of cryptococcal cases [8, 13]. Other risk factors include CD4⁺ lymphopenia, sarcoidosis, renal failure, chronic liver disease, diabetes, and long-term steroid use, tumor necrosis factor- α (TNF- α) inhibitors, solid-organ transplantation, and cancer chemotherapy-induced immunosuppression [13, 68]. The cytokines interferon- γ (IFN- γ) and TNF- α are critical for controlling cryptococcal infection. Individuals with autoantibodies against IFN- γ and granulocyte-macrophage colony-stimulating factor (GM-CSF), which can decrease phagocyte and overall innate immune function, are also vulnerable [54, 69–71]. In Australia, there is a higher rate of *C. neoformans* and *C. gattii* infection in indigenous populations, potentially due to a genetic and/or socioeconomic risk

factor [59, 69]. Smoking and old age were also risk factors for *C. gattii* infection during the Vancouver Outbreak [59].

Antibody deficiency may predispose otherwise immunocompetent individuals to *Cryptococcus* spp. Certain genetic polymorphisms and immune regulation deficiencies are linked to cryptococcal infections, including Fc γ Receptor IIB variants [72, 73], mannose-binding lectin deficiencies [74], IL-12 Receptor deficiency [75], and IgG2 deficiency [62, 69]. Selective antibody deficiencies are hypothesized to render the host unable to mount a protective response to the cryptococcal capsule, a major antigen [59].

Histoplasma

Histoplasma spp., the etiological agents of histoplasmosis, commonly infect otherwise healthy and immunocompromised individuals in highly endemic areas [76]. Two varieties, *H. capsulatum* var *capsulatum* and *H. capsulatum* var *duboisii* account for most human infections. Delayed-type hypersensitivity skin tests in regions of high endemicity suggest that ~90% of residents have been exposed at least once [77, 78]. Most instances of exposure are either self-limiting asymptomatic or acute pneumonic infections exhibiting flu-like symptoms [78]. Only 1% will suffer severe or life-threatening illness and those patients are typically immunocompromised [78].

Though incomplete epidemiology and environmental sampling leaves the true range of endemicity unclear, *Histoplasma* spp. are now considered to span much of the globe [76, 79]. It was initially thought that *H. capsulatum* was primarily constrained to the Ohio and Mississippi River Valleys of North America, with less defined endemicity in Central and South America [77, 80, 81]. A spike in histoplasmosis coinciding with the HIV/AIDS pandemic made it apparent that *Histoplasma* spp. had a wider geographical distribution than initially thought. Among the two of the major varieties, *H. capsulatum* var *capsulatum* is highly endemic in the soils of the Ohio and Mississippi River Valleys of North America, certain regions of South and Central America, and in sub-Saharan Africa [76, 79].

Histoplasma spp. are also endemic in regions of Asia and Oceania, but the range is not clearly defined [82–84]. The geographical range for *H. capsulatum* var *duboisii* does not appear to extend beyond Africa, and overlaps with that of *H. capsulatum* var *capsulatum* in regions of endemicity [85, 86].

In humid to semi-humid river basin habitats, *Histoplasma* spp. grow as a soil-resident spore-forming molds [79]. The haploid filamentous form of *Histoplasma* spp. also produce microconidia (2–5 μ m) and tuberculate macroconidia (8–15 μ m). Microconidia or sexually produced ascospores are likely the most common infectious propagules, as their small size allows them to reach terminal bronchioles.

Histoplasma spp. prefer soil rich in nitrogen, which is typically provided by bat or bird guano. Bats likely serve as a reservoir for *Histoplasma* spp. Bats are susceptible to pulmonary and disseminated *Histoplasma* infections and can shed the fungus in their guano [87, 88], making caves and other bat roosts potential sources for human exposure [87, 88]. Birds are resistant to infection, but natural and urban areas that commonly host high numbers of birds are also likely to be enriched with *Histoplasma* spp. due to high

concentrations of guano. Thus, sites such as riparian habitats, chicken coops, and buildings amenable to roosting birds are also common sites of exposure [87]. Outdoor activities that disturb contaminated soil or guano, such as caving, excavation, and setting up campgrounds can increase the likelihood of inhaling spores [87].

The *Histoplasma* spp. are highly genotypically and phenotypically diverse, which results in a wide range of clinical presentations [89–93]. Although exposure and even self-limiting symptomatic infections are common in endemic regions, life-threatening infections are much rarer. The infecting *Histoplasma* strain, inoculum size, and host status all converge to produce a wide range of presentations including acute and chronic pulmonary infection, mediastinal lymphadenitis, and progressive disseminated infection [94]. Although *H. capsulatum* delays the onset of robust protective immunity through immunoevasive mechanisms discussed later in this review, development of a Th1 dominated response will typically control the infection [95–97].

Infections in immunocompetent individuals can produce asymptomatic to severe flu-like symptoms. In endemic regions, pulmonary nodules are common even in asymptomatic individuals, which can make diagnosis difficult [98]. Progressive dissemination can involve the liver, spleen, bone marrow, lymph nodes, gastrointestinal tract, and the CNS. However, dissemination is typically limited to patients with severe immunodeficiencies [94].

Cell-mediated immunity is critical for controlling *Histoplasma* spp. infection. As with many fungal infections, the most prevalent risk factor for life-threatening histoplasmosis is HIV/AIDS [99, 100]. In hyper-endemic regions, up to 25% of HIV+ patients develop clinical histoplasmosis [101], with highly active antiretroviral therapy decreasing this rate [102]. Additional risk factors include organ/bone marrow transplantation [103, 104], TNF- α inhibitors [105, 106], COPD [102], smoking [76], extremely young or old age [94, 104], and host genetics [107, 108].

For solid organ or bone marrow transplant patients, most histoplasmosis diagnoses appear either within a year post-transplant or greater than 2 years post-transplant [103, 104]. Patients receiving TNF- α blockers are at an increased risk for severe pulmonary histoplasmosis and progressive dissemination, as TNF- α is critical for activating macrophages and limiting intracellular proliferation [105, 106]. COPD and smoking are both risk factors for chronic pulmonary histoplasmosis, especially in the elderly [76]. Infants (<2 years) and the elderly (>50 years) are at an increased risk due to natural immune deficits, especially when compounded with other risk factors [104]. Genetic risk factors potentially include particular major histocompatibility complex (MHC) haplotypes [107], and IFN- γ receptor 1 deficiency [108].

Blastomyces

The geographical range of the major causative agents of blastomycosis, *Blastomyces dermatitidis* and *B. gilchristii*, overlap with *H. capsulatum* in some regions of North America, though *Blastomyces* spp. likely extends further north [109]. *Blastomyces* spp. are prevalent in the Ohio and Mississippi River Valleys, the Great Lakes region, and the St. Lawrence River of the U.S. and Canada [110]. A newly identified species, *Blastomyces*

helicus, appears to cause rare, pathologically distinct disease in the drier western and mountainous regions of the U.S. and Canada [111]. Outside of North America, sporadically reported autochthonous cases occur in Africa and India [112, 113].

In the environment, *Blastomyces* spp. mycelia penetrate soil and detritus, and produce conidia that are 2–10 µm in size. The ecological niches suitable for *Blastomyces* spp. are somewhat poorly defined, but in some ways appear similar to *Histoplasma* spp. *B. dermatitidis* and *B. gilchristii* reside in freshwater drainage basins, and can be commonly isolated in forested areas near lakes and rivers that contain acidic soil, large amounts of decaying vegetation, and bird guano [109, 114, 115]. Outdoor activities that disturb contaminated soil will aerosolize spores and increase the likelihood of exposure [110]. Unlike *Histoplasma*, *Blastomyces* is not known to infect bats or other animals as a means of propagation. However, symptomatic infection is particularly common in dogs and wild canids [116, 117].

Within endemic regions, annual incidence of reported clinical *Blastomyces* spp. infection ranges from <1 human cases/100,000 people to >100 cases/100,000 people during outbreaks in the hyperendemic regions [118, 119]. At least 50% of infections are mild or asymptomatic, and unlike *Histoplasma* spp. there is no reliable assay for prior exposure, so true incidence of infection is undetermined [115]. Blastomycosis commonly presents in immunocompetent patients, and up to 50% of exposures may result in symptomatic pneumonia [115, 120]. However, severe clinical outcomes usually limited to immunocompromised patients. Most clinical cases (50–75%) of blastomycosis are restricted to the lungs [119, 121, 122]. Pulmonary blastomycosis is symptomatically varied, typically presenting as acute or chronic pneumonia [109, 123]. Severity ranges from mild and self-limiting pulmonary infections to acute respiratory distress syndrome (ARDS). ARDS is characterized by a rapidly overwhelming infection, pulmonary edema, and increased mortality [124–126]. *Blastomyces* spp. can also disseminate from the lungs to almost any organ, though it most frequently localizes to the skin [109, 127, 128]. Other common sites of dissemination include bone, the genitourinary system, and the CNS [109].

Risk factors for life-threatening infections include organ transplantation [129], HIV/AIDS [130], and TNF-α inhibitors [131, 132]. Despite cell-mediated immunity being critical for resolving blastomycosis [133, 134], the infection is relatively uncommon in patients with HIV/AIDS, especially compared to cryptococcosis or histoplasmosis [130]. However, HIV/AIDS increases the risk for ARDS and dissemination to the CNS [130]. Just as for histoplasmosis, protective immunity against blastomycosis is reliant on TNF-α [135], meaning TNF-α inhibitors can increase severity of disease [131, 132].

Coccidioides

Coccidioides immitis and *C. posadasii* are the causative agents of coccidioidomycosis, otherwise known as Valley Fever. *Coccidioides* spp. are endemic in the arid deserts of the southwest United States and northern Mexico, with particularly high endemicity in southern Arizona, northwestern Mexico, and the Central Valley of California [136, 137]. Sporadic cases and soil isolates discovered in the arid regions of eastern Washington and northeastern

Utah suggest that the endemic range may be increasing or was greater than originally thought [138–140].

In the soil, *Coccidioides* spp. thrive in their mycelial form. Arthroconidia (spores) are the infectious propagule. They develop from within septate hyphae to form long chains that can dissociate when disturbed. *Coccidioides* can tolerate a wide range of soil pH and temperature, but appears to prefer alkaline sandy soils with high salinity [141–144]. However, arid desert soils are overall less nutrient rich than the river basins harboring *Histoplasma* and *Blastomyces* spp. Possibly due to this relative resource scarcity, the distribution of *Coccidioides* spp. can be patchy; presence of the fungus correlates with high salinity and plentiful essential nutrients such as iron and calcium [141, 144].

Coccidioides spp. are also commonly isolated from animal middens, burrows, and carcasses [143, 145, 146]. Desert-dwelling animals such as rodents have been found with granulomatous *Coccidioides* spp. infections in their lungs [147], and *Coccidioides* spp. can resume hyphal growth in soil following the death of infected animals [148, 149]. Genomic studies indicate that *Coccidioides* spp. evolution has been influenced through interactions with animal hosts, and that the fungus could utilize an expansive repertoire of proteases to access the organic matter from carcasses [150]. These observations suggest that *Coccidioides* spp. may exploit animals and/or their burrows as reservoirs [143, 145, 146]. One caveat is that the most reliable way to isolate environmental *Coccidioides* spp. has traditionally been monitoring disease in laboratory mice inoculated with soil samples [137, 151]. This method is cost-prohibitive and may bias sampling in favor of virulent isolates. A recently developed PCR-based method of detection should improve understanding of *Coccidioides* spp. ecology [152].

Coccidioides spp. soil growth, dispersal, and human infection tend to follow seasonal weather patterns in endemic areas. Milder temperatures allow for optimal mycelial growth [153, 154]. Hot and dry periods facilitate maturation and dispersal of arthroconidia, particularly during strong winds [153, 155–157]. Incidence of human infection often increases during dry seasons, and massive dust storms can carry infectious arthroconidia aloft for miles [153, 155, 156].

Large scale delayed-type hypersensitivity skin testing beginning in the 1950's suggested that ~50% of residents in highly endemic areas had likely been infected [137, 158, 159]. Of those infected, 30–50% were estimated to have developed symptomatic fungal pneumonia [137]. Similar to the other dimorphs, annual incidence of coccidioidomycosis is variable and dependent upon the frequency of activities that increase risk of exposure. There has been a recent uptick in coccidioidomycosis, especially in Arizona and California [137, 160, 161]. This increase in incidence could be due to changing weather patterns, influx of people from non-endemic areas, or urban expansion [137, 161, 162].

Most cases of coccidioidomycosis are self-limiting pneumonias with flu-like symptoms; dissemination occurs in less than 5% of immunocompetent patients [163, 164]. Cell-mediated immunity is critical for resolving disease, and immunocompromising risk factors such as HIV/AIDS [165–168], organ transplantation [169–171], TNF- α inhibitors [131,

172], extreme age [173], and certain genetic polymorphisms [174–176] can increase the severity of clinical outcome and frequency of extrapulmonary dissemination [177]. Though *Coccidioides* can disseminate to almost any organ, common sites include the CNS, skin, bones, and joints [178].

In contrast to cryptococcosis and histoplasmosis, HIV/AIDS does not seem to be as strong of a predictor for *Coccidioides* spp. dissemination to the brain [168, 179]. Underlying genetic or hormonal factors appear to be more significant susceptibility markers for coccidioidal meningitis. Diabetes [180], pregnancy [181, 182], and certain ethnicities (African and Filipino descent) [183, 184] all correlate with increased risk for CNS infection [137, 179]. Extrapulmonary dissemination occurs in ~30% of transplant recipients with coccidioidomycosis, making it a far more frequent occurrence than in the general population [169–171].

The potential genetic risk factors for susceptible populations are still unclear, but polymorphisms in genetic loci critical for proper Th1-mediated immunity have been associated with increased severity of clinical outcome. These include a loss of function deletion in the IFN- γ receptor 1 gene (*IFNGR1* 818del14) [174], and a SNP in the IL-12 Receptor β 1 gene (IL12RB1 C186Y) [175]. Additionally, gain of function mutations in the IFN- γ signal transducer, STAT1, increased susceptibility to both *Coccidioides* and *Histoplasma* spp. [176]. The gain of function mutations increased IFN- γ expression, but decreased responsiveness to IFN- γ restimulation, suggesting that long-term aberrant regulation of Th1 responses impaired immunity to fungal infection [176].

Evidence for latency

In addition to primary exposure immediately progressing to symptomatic disease in susceptible patients, there is clinical evidence in support of long-term persistence of environmentally acquired fungi within immunocompetent individuals. These “latent” infections can progress to symptomatic disease when individuals become immunocompromised. Much of the evidence in support of latent fungal infections comes from cases in which patients developed symptomatic disease years after migrating from endemic regions to nonendemic regions [185]. However, it is unclear how often symptomatic disease is the result of reactivated latent infections, or how the fungi are persisting in these cases. More research is needed to address these questions. For the purpose of this section, we will use “latent” to describe an asymptomatic infection capable of reactivating to symptomatic disease. We use “asymptomatic” to describe a subclinical infection that progresses in some cases, even if rarely. Use of the term “latent” does not, however, make any statement about whether the reactivatable microbe is metabolically dormant.

Aspergillus

Aspergillus spp., particularly *A. fumigatus*, can establish chronic infections in human lungs. There is not currently evidence that these infections are dormant and can be reactivated to cause invasive disease, as is the case for other fungal infections discussed below. Chronic *Aspergillus* spp. infections include aspergillomas and different types of chronic pulmonary

aspergillosis [5, 40]. The latter includes chronic cavitary pulmonary aspergillosis (CCPA) and chronic fibrosing pulmonary aspergillosis (CFPA). Fungal-caused lung cavitations in CCPA can progress to CFPA [5]. Antifungal treatment is necessary for chronic pulmonary aspergillosis [5, 40] but is not recommended for asymptomatic, non-fibrotic aspergillomas due to lack of efficacy [186–188]. Most patients with chronic pulmonary aspergillosis also have underlying lung conditions [5, 189–191]. Aspergillomas are usually asymptomatic but occasionally progress hemoptysis and other forms of lung disease [192].

Aspergillus spp. colonization can also exacerbate inflammatory conditions. An estimated 4 million patients worldwide have allergic bronchopulmonary aspergillosis [193] but diagnosis can take a decade or more [194]. Patients exhibit elevated IgE levels in response to *A. fumigatus* antigens [195, 196]. ABPA is a particular problem for cystic fibrosis patients, in whom ABPA decreases respiratory function [42] and can cause lung fibrosis [41]. Approximately 9% of cystic fibrosis patients are diagnosed with ABPA, whereas 1–3% of asthma patients also have ABPA [197]. Not all cystic fibrosis patients with anti-*A. fumigatus* antigen IgE develop ABPA: genetic variants in HLA genes increase ABPA susceptibility in cystic fibrosis patients [198]. ABPA patients exhibit a Th2 cytokine response [197, 199], a common trait among fungal infections that predicts worse patient outcomes [200, 201].

Cryptococcus

Cryptococcus spp. cells can survive within pulmonary granulomas for years before reactivating to clinical disease under the right circumstances [11, 185, 202]. One study compared patient and environmental *C. neoformans* isolates from patients diagnosed with HIV/AIDS and cryptococcosis several years after immigrating to France from Africa [203]. They found that the strains isolated from the migrant patients were more similar to environmental isolates from Africa than Europe. This suggests that patients acquired *Cryptococcus* years prior to immunosuppression and diagnosis of fungal infection [203]. Autopsies have also revealed evidence of latent cryptococcal pulmonary nodules in patients who died of unrelated causes [204]. Furthermore, an association between increased sera reactivity against cryptococcal antigens and an increased risk for cryptococcal infections in transplant patients may indicate reactivated latent *Cryptococcus* as the source of infection. In a study that tested sera from transplant patients collected prior to transplant, patients who acquired cryptococcosis after transplantation showed more reactivity to cryptococcal proteins (52%) compared to approximately 9% reactivity among patients without cryptococcosis [205].

C. neoformans cells within granulomas may be able to achieve latent metabolic dormancy [206]. Long-term *C. neoformans* infection can be modeled in rats, where *C. neoformans* cells can survive for years in lung granulomas without clinical signs of illness and little to no cryptococcal cell growth in extrapulmonary organs [12]. While the metabolic state of these cells is unknown, immunosuppression with dexamethasone resulted in reactivation of fungal growth and extrapulmonary dissemination [12]. Additional work demonstrated that subclinical cryptococcal infection also worsened experimentally induced allergic inflammation within the lungs [207]. The ability of *C. gattii* to establish latent infections is less clear [59].

Histoplasma

There is some evidence that *Histoplasma* spp. can remain latent within granulomas for decades with potential for reactivation [208–211]. Reactivated histoplasmosis in transplant recipients from endogenous and donor-derived infections has also been documented [103, 212, 213]. Due to the high likelihood of repeat exposure in endemic regions, it is difficult to assess the frequency of latent infections. Evidence for latency is also derived from imported cases in non-endemic regions that occur years after the patient left an endemic area [208–211]. A new assay for *Histoplasma* latency assesses interferon gamma (IFN- γ) release by a patient's T lymphocytes when stimulated with *H. capsulatum* crude antigens; latently infected patients should exhibit increased IFN- γ [214].

Blastomyces

Blastomyces spp. can also remain latent for long periods within human lungs. The onset of primary blastomycosis can range dramatically from several weeks to months [215]. Delayed onset of clinical disease complicates pinpointing the source of outbreaks. Additionally, reactivation of latent blastomycosis has been documented [130, 216]. For example, in a set of HIV/AIDS patients, blastomycosis was diagnosed in patients who had not resided in endemic areas for several years [130]. The host and fungal responses that could lead to long-term latency are unknown but could involve a non-sterilizing granulomatous response following primary infection [185].

Coccidioides

A strong case for latent infection leading to reactivated coccidioidomycosis comes from transplant recipients. Up to 70% of cases in transplant recipients are diagnosed within one year of transplantation, and 50% occur within three months [169, 217]. Additionally, among a group of 13 patients who had acute coccidioidomycosis 1–4 years prior to transplantation, 11 developed coccidioidomycosis following transplantation [217]. Reactivated coccidioidomycosis can potentially occur decades after acute infection, as one patient developed disease 56 years after moving from California to non-endemic Spain [218].

Fungal factors promoting infectivity and virulence

Survival and evasion of early host immune responses in the lung are critical for establishing fungal infections and distinguish potential pathogens from other commonly inhaled but innocuous environmental fungi. Some of the strategies employed by environmental fungi are common across species, perhaps suggesting similar selective pressures in their native environments [219–222]. Others vary considerably. We provide an overview of early lung infectivity as a primer to readers new to the medical mycology field.

Fungi use many strategies to survive interactions with the host's immune system. Inhaled fungi face a largely inhospitable environment and must overcome a number of trials in order to survive and establish infection. The human airways are continually flushed by mucociliary clearance and invading fungal cells must initially be small enough to penetrate terminal bronchioles and alveoli where they might replicate [223]. Fundamental prerequisites for fungal infectivity include thermotolerance at 37 °C, and the capabilities for

acquiring nutrients in the host environment, especially limiting nutrients sequestered by the host [30, 224]. Metabolic adaptations to the host environment are extensive and are reviewed elsewhere [225]. During passage from the oral cavity to the lungs, conidia are exposed to airway epithelial defenses, and phagocytes deep in the lungs, particularly alveolar macrophages and neutrophils [226]. Fungi must survive attacks by phagocytes, germinate if the infectious propagule is a spore or conidium, and replicate in a nutrient-limiting, hypoxic environment. Many environmental fungal pathogens exhibit overlapping survival strategies to 1) grow within the host, 2) change their cell surfaces to survive host defenses, 3) evade and/or survive phagocytosis, and 4) manipulate host responses via secreted products.

Host-associated morphology and growth:

All of the environmental fungi highlighted here produce some form of small (usually < 5 μm) cell as their primary infectious propagule. These propagules must evade or survive host immune recognition, in order to establish an infection. For instance, conidia are asexual spores that serve as the infectious propagules for *Aspergillus*, *Histoplasma*, *Blastomyces*, and *Coccidioides* spp. Conidia are frequently $\sim 5 \mu\text{m}$, which allows them to easily aerosolized and reach terminal bronchioles and alveoli. *Cryptococcus* does not produce asexual conidia; basidiospores (produced via either bisexual or unisexual mating [227]) and desiccated yeast cells are the most likely infectious propagules [11, 13, 53, 228]. Once in the lungs, conidia germinate into vegetative fungal forms through extensive cell wall remodeling. These changes alter exposure of pathogen-associated molecular patterns (PAMPs), triggering immune recognition.

Aspergillus—*Aspergillus* spp. conidia germinate as hyphae, and if left unchecked can cause large mycelial lesions in the lungs [40]. *Aspergillus* is obligately filamentous, and is the only fungal pathogen discussed here that undertakes hyphal growth in the host. Although *Cryptococcus neoformans* occasionally produces pseudohyphae within host tissue, *Cryptococcus* spp. hyphal growth is generally restricted to mating and is associated with greatly reduced virulence [229]. Following germination, *Aspergillus* forms a complex network of hyphae known as a mycelium. The hyphae can penetrate lung tissue [230] and form aspergilloma, or “fungal balls,” within the lung space. Aspergillomas’ central cores consist of mycelia and extracellular polysaccharides [231], with immune cells and dead tissue on the periphery. They are initially asymptomatic but occasionally enter blood vessels and can cause hemorrhage [5, 40]. Aspergillomas represent a usually asymptomatic form of infection that allows fungal persistence and can progress to severe disease [40].

Cryptococcus—*Cryptococcus* spp. grow predominantly as budding yeasts. The mating process has been extensively reviewed elsewhere [227, 232], but sexual mating involves the fusion of two cells of opposite mating type (**a** and α), which undergo hyphal growth post-fusion. After nuclei fuse, basidia form at the ends of hyphae, where meiosis and spore formation occur [232]. Spores are thought to be the primary infectious propagule of *Cryptococcus* spp., are resistant to environmental stresses [233], and are virulent in mouse inhalation models of cryptococcosis [228, 234]. *Cryptococcus* spp. can also undergo unisexual mating [235, 236]. Since the α mating type predominates among *C. neoformans* isolates and the **a** mating type was thought extinct until 2003 [237], the existence of

unisexual mating [235, 238] provides a possible mechanism for formation of infectious propagules [227, 239].

Within the host lungs, *C. neoformans* remains a budding yeast but displays enormous pleomorphism. In typical laboratory growth media, cryptococcal yeast cells are 5–7 μm in diameter [53]. A pulmonary infection, however, consists of cells ranging from 2–100 μm in size [240–242]. The differentiation of a subpopulation of cryptococcal cells into “titan cells” is particularly striking. Polyploid and ranging from 15–100 μm diameter, titan cells have a thicker cell wall and a densely cross-linked capsule. Titan cells are resistant to phagocytosis and decrease phagocytosis of nearby smaller cells, which may allow them to promote long-term infection [243]. Environmental stimuli such as low nutrients, hypoxia, acidic pH, serum, and bacterial components can influence the generation of titan cells [244–246]. G-protein coupled receptor 5 and Ste3a are important for titan cell formation and signal through Gpa1 and the cAMP/PKA pathway [244–247]. This in turn activates the transcription factor Rim101, which is required for titan cell formation, and also regulates morphological transitions in *Candida albicans* [245, 247, 248]. Titan cells are rarely observed outside of the lungs, but can bud smaller haploid daughters which may be more likely to disseminate [53, 240, 249]. Additionally, titan cells exhibit resistance to oxidative stresses [240], making them particularly suited for early infectivity.

Histoplasma—The “dimorphic” pathogens *Histoplasma*, *Blastomyces*, and *Coccidioides* spp. are so named because they have evolved morphogenetic programs coordinating the transition from environmental spore-forming molds to host-associated yeast/spherules. Virulence of these fungi is dependent on this transition, as yeast do not appear to be required for their environmental life-cycles [16]. Rather, the yeast-phase transition represents a specific program for pathogenesis [16, 250–252]. The predominant environmental cue for all of these dimorphs is the shift from ambient (i.e. 25°C) temperature to core human body temperature (37°C). The import of exogenous cysteine is also necessary to initiate mitochondrial respiration and growth in recently transformed *Histoplasma* and *Blastomyces* yeast [253–255]. Elevated CO₂ tension (5% CO₂) in lung alveoli facilitates *Coccidioides* phase transition and enhances growth of *Histoplasma* yeast [160, 256, 257].

The genetic elements governing hyphal-to-yeast-phase transition by dimorphic fungal pathogens are best understood in *Histoplasma*. The transcription factors Ryp1, Ryp2, Ryp3, and Ryp4 [258–260] are all absolutely necessary for yeast form growth. The Ryp (Required for Yeast-Phase Growth) transcription factors form a positive feedback network to regulate themselves, the other three Ryp proteins, and broad yeast-phase transcription. Each Ryp protein is capable of associating with the *RYP1*, *RYP2*, and *RYP4* promoters to induce transcription. The *RYP3* gene, although not directly bound by any of the Ryp proteins, still indirectly requires them for its expression [260]. Veal [261] and the histidine kinase Drk1 also positively regulate the transition to yeast [262]. Veal is required for the transition to yeast phase, but not its maintenance. The molecular mechanisms leading to initial upregulation of Ryp proteins and the potential links between the Ryp transcription factor network and Drk1 are unknown. Drk1 could facilitate signal transduction leading to *RYP* gene upregulation, but its phosphorylation targets have not been solidified [263].

Blastomyces—*Blastomyces* spp. yeast are multinucleate, and can be distinguished from *Histoplasma* spp. yeast under light microscopy by their broad-based bud neck and doubly refractile cell wall [255]. Despite these morphological differences, at least one of the factors governing yeast phase transition in *B. dermatitidis* overlaps with *H. capsulatum*. RNAi silencing of *DRK1* in *B. dermatitidis* completely prevents transition to yeast, and renders *B. dermatitidis* avirulent [262]. The *RYPI*–4 genes governing yeast phase transition in *H. capsulatum* are also conserved in *B. dermatitidis*, but functional studies related to these genes in *Blastomyces* spp. have not yet been carried out [255, 260].

Coccidioides—*Coccidioides* spp. arthroconidia differentiate into a host-specific form, but the morphology of *Coccidioides* spp. is dramatically different from *Histoplasma* and *Blastomyces* spp. yeast. Individual arthroconidia first adopt a more spherical form (spherules) via isometric growth. As they grow, spherules form an outer shell via synchronous internal division of their nuclei and cytoplasm, and the inner section fills with hundreds of individual (2–4 μ m) endospores [160, 264]. Mature spherules can measure 20–100 μ m across. As with cryptococcal titan cells, mature spherules are too large to be engulfed by host phagocytes. When a spherule ruptures, it releases its endospores, which can then differentiate into new multi-endospore spherules. Lack of reliable methods for targeted genetic manipulation of *Coccidioides* has hampered the molecular understanding of the mechanisms mediating the arthroconidia to spherule transition. However, some insights have been made through comparative transcriptomic and proteomic studies performed on the mycelial and spherule forms [265–267]. For instance, *Coccidioides* spp. have homologs of *DRK1* and *RYPI*–3 genes. None of these genes are significantly upregulated in *Coccidioides* spherules, but their contribution to phase transition is still unclear [265, 266]. For instance, *DRK1* is also not overexpressed in *B. dermatitidis* yeast, despite Drk1 being necessary for yeast phase transition [262].

Cell surface remodeling:

In addition to large-scale morphological changes, environmental fungal pathogens often alter their cell wall composition or surface exposure during infection. Fungal cell walls contain many pathogen associated molecular patterns (PAMPs), such as β -glucans and chitin. However, fungal cells often employ various mechanisms that mask inflammatory carbohydrates in the cell wall, allowing them to avoid or delay stimulation of the host immune system. For the fungi discussed here, this generally involves decorating the outer layer of the cell with less immunostimulatory molecules and/or reducing the content of immunostimulatory cell wall components.

Aspergillus—The outer surface of *A. fumigatus* conidia is comprised of hydrophobin protein rodlets over a layer of melanin. Beneath these layers, the conidial cell wall is rich in PAMPs, such as β -(1,3)-glucan and mannoproteins [268]. The germination rate is a major driver of immune cell detection, as germination induces changes in the fungal cell [269]. As conidia swell, PAMP exposure increases, rendering the fungi more easily detectable by host defenses. Swelling damages protective surface hydrophobins [270] and exposes β -(1,3)-glucan and other cell wall components [270–272]. β -(1,3)-glucan is detected by the dectin-1 receptor [273], which is essential for host defense against *A. fumigatus* [274]. Recognition

of β -(1,3)-glucan activates signaling pathways which result in IL-8 upregulation [275]. IL-8 recruits neutrophils, which efficiently destroy *A. fumigatus* [275].

In contrast to conidia, *A. fumigatus* hyphae are coated in polysaccharides that facilitate infectivity and create a protective extracellular matrix (ECM). These secreted polysaccharides are predominantly galactomannan and galactosaminogalactan (GAG) [276]. GAG is synthesized within the cell, then cleaved by a plasma membrane-localized protein that is essential for infectivity and GAG production [277]. ECM facilitates biofilm formation *in vitro* [276] and in the lungs [278], protecting mycelia from immune cells.

Cell surface changes are also tied to stress adaptation responses [279], which are in turn linked to nutritional adaptation to the lung environment [26, 280, 281]. The connections between pathways controlling different aspects of environmental responsiveness emphasize the importance of the fungi's ability to rapidly adjust to changing environments within the host.

Cryptococcus—*Cryptococcus* spp. cells rapidly expand their polysaccharide capsule *in vivo*, and capsule alone can more than double the size of a yeast cell [242, 282]. Capsule composition is ~90% glucuronoxylomannan (GXM), ~10% galactoxylomannan (GXMGal), and ~1% various mannoproteins by mass [242, 282]. Capsule is non-covalently attached to α -(1,3)-glucan in the cells wall, and deletion of the α -(1,3)-glucan synthase gene (*AGSI*) results in cells that still secrete capsule polysaccharide, but cannot maintain it on the cell surface [283]. Capsule production is stimulated by environmental cues that include low iron [284], host carbon dioxide levels [285], pH, nutrient availability [286], and additional stresses [242, 282]. The transcription factor Rim101/PacC enables *C. neoformans* to sense extracellular pH and adapt its cell surface structure to evade immune stimulation [287–289]. Acapsular strains are avirulent in animal models, and are rarely if ever observed clinically [290–292]. *C. neoformans* is also able to synthesize melanin and incorporate it into its cell wall [293]. Strains able to produce melanin showed less susceptibility to reactive oxygen species than strains lacking melanin [294]. Melanin may also protect against microbicidal peptides such as defensins and can interfere with ingestion by phagocytic cells [294, 295].

Histoplasma—*Histoplasma* spp. yeast go to great lengths to shield cell wall β -glucans from the host. The cell walls of *H. capsulatum* yeast, but not mycelia, are highly decorated with α -glucan which cloaks underlying β -glucans from detection by the host pattern recognition receptor dectin-1 [296]. Remarkably, α -(1,3)-glucans are upregulated to such a degree in *H. capsulatum* yeast that during co-infection with *C. neoformans*, *H. capsulatum* can capture secreted cryptococcal GXM, providing further shielding from the immune system and heightened virulence [297]. RNAi-mediated suppression of *H. capsulatum*'s α -(1,3)-glucan synthase (*AGSI*) attenuates virulence in mice due to increased recognition of fungal cells and the resultant production of proinflammatory cytokines such as TNF- α [298, 299]. Furthermore, *Histoplasma* yeast secrete the glucanases Eng1 and Exg8 to further reduce β -glucan exposure [300, 301].

Interestingly, not all strains of *H. capsulatum* mask β -glucan with α -(1,3)-glucan [302]. *H. capsulatum* is divided into chemotype I and chemotype II strains based on cell wall

characteristics. While chemotype II yeast cell walls contain high levels of α -(1,3)-glucan, chemotype I yeast poorly express *AGSI*, and lack apparent α -(1,3)-glucan in their cell wall during yeast-phase growth *in vitro*. Additionally, when *AGSI* is completely inactivated in chemotype I cells, they maintain virulence [302, 303], and can evade dectin-1 recognition [302]. Loss of Eng1 and Exg8 in both chemotypes increases dectin-1 recognition of β -glucan, indicating that β -glucanses in the chemotype I strains could at least partially compensate for the lack of α -(1,3)-glucan [300, 301].

Blastomyces—Masking inflammatory carbohydrates in the cell wall may also help *Blastomyces* yeast prolong immune evasion. Compared to hyphae, yeast have less β -glucan and increased α -glucan content [304]. β -glucans comprise ~40% of the hyphal cell wall, but only ~5% of the yeast cell wall [304]. This suggests a strategy similar to *Histoplasma*, in that yeast mask β -glucan to avoid immune stimulation through Dectin-1 or other host receptors [305].

Coccidioides—In *Coccidioides* spp., cell surface genes are among the most differentially expressed genes when comparing mycelial to spherule growth, highlighting their importance in phase transition and adaptation to the host environment [265, 266]. *Coccidioides* spherules also upregulate transcription of the α -(1,3)-glucan synthesis gene *AGSI* [265, 266], and dectin-1 recognition of *Coccidioides* contributes to host defense [306]. However, the relative content and exposure of α - and β -glucans in *Coccidioides* mycelia and spherules is unknown. *Coccidioides* chitin-related genes also display significant differential expression between the mycelial and spherule forms, including chitinase genes [265, 266]. Inactivation of two chitinase genes (*CTS2* and *CTS3*) blocks endosporulation within maturing spherules and renders strains avirulent [307].

Interactions with host phagocytes:

The human lung mucosa is under constant immunosurveillance, particularly by patrolling alveolar macrophages and dendritic cells (DCs). These phagocytes express an array of innate pattern recognition receptors and efficiently recognize and destroy invading fungi. They also recruit additional immune cells via cytokines and chemokines to control infection and provide a key link to adaptive immunity by presenting antigen in the draining lymph nodes. Fungal pathogen success during infection often involves limiting recognition by the innate immune system and surviving early interactions with phagocytes [226]. None of the fungal pathogens we discuss completely evade phagocytosis, and all of them have methods of surviving or subverting the microbicidal functions of the phagolysosome. In particular, *Cryptococcus* and *Histoplasma* spp. survive and even proliferate within macrophages to the extent that they are considered facultative intracellular pathogens.

Aspergillus—The initial host defense against *Aspergillus* spp. conidia are airway epithelial and endothelial cells [308] and macrophages [309], but germinating conidia and hyphae are damaged or destroyed primarily by neutrophils [310]. Epithelial and endothelial cells endocytose conidia [308, 311] and are then damaged by the conidia via a mechanism that requires conidia viability [311]. If conidia survive the airway and enter the lungs, they are frequently phagocytosed and destroyed by alveolar macrophages, particularly alternatively

activated macrophages expressing Arg1 [312]. Alveolar macrophages efficiently kill conidia *in vitro*, though killing seems to be delayed until conidial swelling occurs [313]. Conidia can also prolong survival in phagocytes by manipulating phagolysosome maturation. For instance, conidial cell wall melanin inhibits phagolysosome acidification in macrophages and neutrophils [314, 315].

Neutrophils are the primary defense against aspergillosis and neutropenia the major risk factor for invasive aspergillosis [37]. Neutrophils do not kill conidia but they do prevent conidial germination [316] regardless of opsonization [317]. Hyphae [318], particularly opsonized hyphae [317], are killed by neutrophils in a complement-dependent manner [319]. *A. fumigatus* will even form a new hyphal tip at a distal site following interactions with neutrophils or physical (e.g. barrier) or biological (e.g. removal of key nutrient) growth blocks to hyphal growth [320]. The secreted polysaccharide galactosaminogalactan partially protects hyphae from neutrophil by increasing resistance to neutrophil extracellular trap formation [321].

Cryptococcus—Alveolar macrophages interact with *C. neoformans* cells within 2 hours of infection [322]. *Cryptococcus* spp. cells efficiently evade alveolar macrophages via their distinctive polysaccharide capsules. Acapsular strains are easily phagocytosed and cleared from the lungs [322], and the extracellular cryptococcal cells tend to exhibit larger capsule sizes than intracellular fungi [323]. Additionally, capsular polysaccharide that detaches from the fungal cell accumulates within macrophages and dysregulates functions such as cytokine release and antigen presentation [324–326]. Not only do *Cryptococcus* spp. have methods of resisting phagocytosis, but they are also quite capable of operating as facultative intracellular pathogens. Studies in zebrafish show >50% of cryptococcal cells are internalized by phagocytes within 24 hours of inoculation [323]. The fungus can replicate within the phagolysosome due to its ability to survive at low pH [327], and can subsequently escape from macrophages via lytic [326, 328] and non-lytic mechanisms [329–332]. However, alveolar macrophages are capable of playing a protective role, as fungal burden in mice is enhanced when alveolar macrophages are depleted [333]. Additionally, decreased phagocytosis reduces antigen processing and stimulation of T- cell proliferation [282, 334, 335].

Histoplasma—*Histoplasma* spp. takes their intracellular lifestyle one step further than *Cryptococcus* spp. *H. capsulatum* conidia and yeast are phagocytosed by alveolar macrophages within 10 minutes and readily proliferate within macrophage phagolysosomes, often leading to macrophage lysis [336–338]. The majority of yeast will remain intracellular over the course of infection [336–338], and the fungus can disseminate within macrophages to reach tissues such as the liver, spleen, bone marrow, and CNS [94]. Compared to macrophages, dendritic cells display better fungicidal and inflammatory activity against *H. capsulatum*, so proliferation within macrophages also provides a niche to escape further immune detection [339].

H. capsulatum facilitates macrophage adhesion and phagocytosis by localizing a small amount of the heat shock protein 60 (Hsp60), normally a cytoplasmic protein, to the cell surface. Hsp60 is recognized by macrophage CD18-family receptors such as complement

receptor 3 (CR3) to induce phagocytosis [340]. Dendritic cells also express CD18-family receptors, but do not rely on them for phagocytosis of *Histoplasma*. As dendritic cells are much better at killing and processing *Histoplasma* yeast for antigen presentation [341], localization of Hsp60 to the cell surface may represent a targeted means for *Histoplasma* yeast to enter their macrophage safe havens [342]. Additional traits important for survival in phagolysosomes, such as acquisition of the limiting nutrients iron and zinc, are reviewed elsewhere [343, 344].

Proliferating intracellular *H. capsulatum* yeast eventually lyse macrophages, after which they can spread to additional macrophages nearby. Macrophage lysis appears to be regulated at least in part by the yeast-specific calcium-binding protein 1 (*CBP1*) gene through the activation of host caspases [345, 346]. *CBP1* is not necessary for maximal proliferation within macrophages *in vitro*, though disruption of *CBP1* does result in delayed proliferation and reduce lung fungal burden in mice [345]. This indicates that macrophage lysis is a critical step in perpetuating *Histoplasma* proliferation.

Blastomyces—*Blastomyces* spp. are not dedicated intracellular pathogens, and often appear in extracellular spaces in histological samples [110, 347, 348]. There is also no current evidence *Blastomyces* spp. disseminate at a high frequency within macrophages. However, *Blastomyces* spp. still must overcome initial interactions with alveolar macrophages. Phagocytosis of *B. dermatitidis* conidia by alveolar macrophages begins within an hour of murine pulmonary infection [349]. Within 24 hours, 30–70% of *B. dermatitidis* cells appear to be intracellular, and can be predominantly found within alveolar macrophages [349, 350]. Conidia are highly susceptible to killing by innate immune cells such as macrophages and neutrophils, while *B. dermatitidis* yeast cells tend to be more resistant due to their ability to suppress the production of toxic nitric oxide during alveolar macrophage infection [351–353].

Conidia that do survive phagocytosis can germinate into yeast cells and replicate within murine alveolar macrophages [349]. Depletion of alveolar macrophages and dendritic cells actually reduces early fungal proliferation of *B. dermatitidis* in the lungs, suggesting that macrophages might be an initial niche for *B. dermatitidis* germination into yeast and replication [349]. Alveolar macrophages are not completely permissive to *B. dermatitidis* yeast, and can kill the fungus [354]. However, *B. dermatitidis* yeast within alveolar macrophages may be sheltered from more efficient killing by infiltrating neutrophils and monocyte-derived macrophages [352]. Previous exposure to *B. dermatitidis* enhances macrophage activity against the fungus [355], at least partially due to lymphocyte derived IFN- γ [356–358].

Coccidioides—Mature *Coccidioides* spp. spherules can reach 100 μm in size, which makes them too large to be engulfed by alveolar macrophages. However, inhaled arthroconidia and endospores released from ruptured spherules are certainly small enough to be phagocytosed. These smaller forms of *Coccidioides* spp. have subtler mechanisms that protect them from macrophage killing [348]. For example, *Coccidioides* spp. cells time the expression of an immunogenic cell surface protein to reduce opsonic phagocytosis. Mature spherules express SOWgp (spherule outer wall glycoprotein), which decorates the outer wall

of spherules, and likely enhances adhesion to host tissues through interaction with various extracellular matrix proteins [265, 359, 360]. Loss of the *SOWgp* gene significantly attenuates virulence [359, 360]. However, antibodies generated against SOWgp lead to increased phagocytosis and killing of *Coccidioides* [361]. To avoid SOWgp-mediated detection, small endospores released from mature spherules secrete the metalloprotease Mep1 in order to degrade SOWgp on the endospore surface [361].

Additionally, alveolar macrophages that phagocytose *Coccidioides* spp. arthroconidia typically display poor fungicidal capabilities in the absence of help from lymphocytes [362, 363]. *Coccidioides* spp. arthroconidia can also transition to immature spherules within macrophage phagosomes, and appear to prevent phagosome-lysosome fusion [362, 363]. Similar to *B. dermatitidis*, *Coccidioides* spp. can suppress toxic nitric oxide production by macrophages [364], which may partly explain why pulmonary infection of mice with nitric oxide deficiencies has little effect on *Coccidioides* spp. pathogenesis [365, 366].

Secreted immunomodulatory factors:

A hallmark of plant and insect fungal pathogens is their expansive repertoire of secreted proteins, many of which are virulence factors that help shape a suitable microenvironment for fungal infection [367]. Although fungi capable of infecting mammals appear to harbor significantly fewer genes for secreted proteins, there are some notable examples [367]. Some of these secreted factors aid in counteracting the defense of the host's immune system, whereas others drive fungal adhesion and dissemination.

Aspergillus—*Aspergillus fumigatus* produces a number of factors that block host defenses and facilitate fungal survival. During the initial phagocytosis process, conidia are directed to the phagolysosome within macrophages, where they are destroyed by acidification and reactive oxygen species (ROS). Fungal products such as melanin protect against ROS [368, 369] and secreted catalases and oxydases block the formation and release of ROS by the host [370]. Fungal secreted proteases damage lung elastin and collagen I [371], which facilitate hyphal penetration of host tissue, fungal spread, and adhesion. This tissue damage also aids binding of conidia; when tissues are damaged, fibrin and fibronectin form at damaged sites. This damage recruits inflammatory cells and facilitates fungal adhesion [372]. Sialic acid on *A. fumigatus* conidia adheres to fibrinogen [373] and fibronectin [374], recruiting fungal cells to sites of tissue damage. The protein Asp2 also binds host factors such as plasminogen, which is cleaved to plasmin and facilitates tissue invasion by damaging the lung extracellular matrix [375]. Asp2 also binds factor H to conidial surfaces, which facilitates the cleavage of complement component 3b [376], downregulating the complement cascade.

Protein secretion by *Aspergillus* spp. is critical for infection. So many proteins are secreted that the Unfolded Protein Response (UPR) pathway is induced, and a UPR signaling-deficient mutant is deficient in lung tissue growth [377]. Many of the tissue-damaging degradative enzymes secreted by *A. fumigatus* evolved to damage plant tissue but can also harm mammalian tissue [370]. Fungal elastases, which degrade elastin in lung alveoli [371], are common among clinical isolates and correlated with invasive disease [378, 379], whereas

strains without elastase activity are correlated with noninvasive, asymptomatic infections [379] or lack of pathogenicity [378].

Cryptococcus—*Cryptococcus* spp. secrete a multitude of enzymes that drive pathogenesis. Cryptococcal urease activity in the lungs promotes a non-protective Type 2 immune response, and an accumulation of immature dendritic cells [380–382]. Urease also facilitates fungal transversal of the blood brain barrier [383]. Like *Candida albicans* and *Aspergillus fumigatus*, *Cryptococcus* spp. secrete phospholipase B, which enhances virulence [384, 385]. Phospholipase B activity enhances adhesion to respiratory epithelial cells [386], and is critical for survival within macrophages [387, 388]. Phospholipase B appears to be attached to the cell wall [389], and is secreted via Sec14, a phosphatidylinositol transfer protein [390]. *C. neoformans* also secretes the metalloprotease Mpr1, which is required for CNS infection [391]. Mpr1 is sufficient for crossing *in vitro* blood brain barrier models. Expression of cryptococcal *MPR1* in *Saccharomyces cerevisiae* allowed the species to cross an *in vitro* blood brain model, when it is normally incapable of doing so [392, 393]. Mpr1 may facilitate transversal of the blood-brain barrier by stimulating cytoskeletal reorganization through interactions with Annexin A2 [393]. Cryptococcal cells use this interaction in conjunction with the endothelial receptor EphA2 to successfully cross the blood brain barrier [394].

C. neoformans also secretes its primary cell surface polysaccharide GXM as a soluble exopolysaccharide (exo-GXM), which systemically suppresses inflammation [324]. Exo-GXM accumulates in the serum and infected tissues into the high µg/ml range [395, 396], upregulating non-protective cytokines such as IL-10 and IL-4 while downregulating IL-2 [282, 397]. Exo-GXM also inhibits T cell proliferation *in vitro* [398], induces T cell apoptosis during antigen presentation [399], and suppresses immune cell infiltration into sites of infection [400–402].

Histoplasma—*H. capsulatum*'s intracellular lifestyle depends on secreted factors that are essential for survival and proliferation in an otherwise microbicidal environment. For instance, *H. capsulatum* yeast, but not mycelia, secrete superoxide dismutase Sod3 and catalase CatB to disable damaging ROS produced by macrophages [250, 403, 404]. Sod3 converts reactive oxygen species to hydrogen peroxide, which is then degraded by CatB. Both yeast and mycelia produce an intracellular oxygen dismutase (*SOD1*) and catalase (*CATP*), neither of which are individually necessary for virulence [250, 404]. CatB and CatP play redundant roles *in vivo*, as the *CATB/CATP* double mutant is attenuated for virulence in mice, while the single mutants maintain wild-type virulence [404].

Blastomyces—The yeast phase transition in *Blastomyces* spp. is also accompanied by an upregulation of secreted proteins, including transcription of its own superoxide dismutases (*SOD2* and *SOD3*) [405]. However, the most highly upregulated gene in yeast during pulmonary infection is the canonical virulence factor *BAD1* [405]. Bad1 is a secreted, multifunctional protein whose main functions are adhesion and immunosuppression. The C-terminus of extracellular Bad1 can bind cell wall chitin [406] and promotes adhesion to host cell surface receptors heparin sulfate [407, 408]. Fungal-bound and soluble Bad1 suppresses release of the critical cytokine TNF-α from macrophages and neutrophils by interacting with

CR3 [135, 409, 410]. While fungal-bound Bad1 suppresses TNF- α through the induction of TGF- β , soluble Bad1 acts through a TGF- β - independent mechanism [409]. Bad1 can also suppress T-cell activation and secretion of host- protective cytokines IL-17 and IFN- γ [407]. Although complete loss of Bad1 renders *B. dermatitidis* essentially avirulent, the adhesive and immunosuppressive properties of Bad1 can be uncoupled. Deletion of just the C-terminal domain impairs adhesion, but does not reduce the immunosuppressive properties of the soluble protein and has little effect on virulence in mice [406].

A more recently identified immunomodulatory virulence factor in *Blastomyces* is dipeptidyl-peptidase IVA (DPPIVA) [411]. This secreted protease is a molecular mimic of human CD26, a peptidase that degrades chemokines and has regulatory roles in hematopoiesis. *Blastomyces* DPPIVA cleaves granulocyte-macrophage colony stimulating factor (GM-CSF) to block maturation and activation of leukocytes [411]. RNAi-mediated silencing of DPPIVA greatly reduces fungal burden during murine lung infection [411].

Coccidioides—Compared to plant-associated members of the sister order Eurotiales, *Coccidioides* spp. genomes contain an expansion of proteolytic enzymes such as keratinases and extracellular serine proteases, which may benefit a life-style that is closely associated with both living animals and carcasses [150]. During pulmonary infection, *Coccidioides* spp. produce ammonia, which creates an alkaline microenvironment that contributes to host damage and fungal survival [347, 412]. Urease, which is released when endospore ruptures, contributes to ammonia buildup and creating an alkaline microenvironment [412]. Urease catalyzes extracellular urea to produce ammonia, and the urease deficient mutant is hypovirulent in mice [412].

Discussion

Fungal diseases are often considered diseases of immunocompromised patients. Severe systemic fungal infections are typically associated with severe immunodeficiencies, particularly due to HIV/AIDS, or immunosuppressive therapeutics used for transplants and cancer chemotherapy. However, fungal infections can commonly result in milder clinical outcomes in those with stronger immune systems. Exposure to *Cryptococcus* spp. and the dimorphic fungi commonly result in latent infections lasting up to decades in immunocompetent hosts. The dimorphs also regularly cause symptomatic respiratory tract infections in otherwise healthy individuals. Whether a fungal infection remains subclinical or not depends primarily on the host condition; benign infections in the immunocompetent become systemic when patients become immunocompromised.

Why there are relatively few fungi that have evolved mammalian virulence remains largely speculative. Recently, the environmental lifestyle of these fungi has been appreciated with respect to human virulence. For instance, it is hypothesized that virulence in *Cryptococcus* spp., and potentially other environmental fungi, evolved through selection in the natural soil environment. *C. neoformans* interacts with a multitude of unicellular soil organisms, including predators such as amoebae and nematodes [219]. Amoebae can readily phagocytose *Cryptococcus* spp. [219], but phagocytosis is reduced by polysaccharide capsule induction, just as it is for macrophages [219, 413]. Similar interactions with

amoebae are observed for other fungi [249]. The tightly regulated thermal dimorphism of *Histoplasma* and *Blastomyces* spp. and their preference for guano-fertilized soil suggest that these fungi may have evolved alongside animals such as bats [414]. This relationship could have maintained a potential for virulence in other mammals, including humans. Finally, growing evidence suggests that *Coccidioides* spp. are associated with small desert mammals, which could serve as a reservoir or a selection for virulence attributes [415]. Despite these advances, our knowledge of their environmental lifestyles still severely lags behind our understanding of host-pathogen interactions. Further studies on the evolution of human disease-causing traits are critical for understanding the pathogenesis of environmental fungi.

Acknowledgments

This work was supported by research grant R01AI130248 from the National Institutes of Health to J.C.S.B. S.T.D. is supported by grant T32AI055434 from the National Institutes of Health.

References

- [1]. Hawksworth DL, Lücking R. Fungal Diversity Revisited: 2.2 to 3.8 Million Species. *Microbiology Spectrum*. 2017;5.
- [2]. Taylor LH, Latham SM, Woolhouse MEJ. Risk factors for human disease emergence. 2001;356:983–9.
- [3]. Köhler JR, Casadevall A, Perfect J. The spectrum of fungi that infects humans. *Cold Spring Harbor perspectives in medicine*. 2015;5:a019273–a.
- [4]. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden Killers: Human Fungal Infections. *Science Translational Medicine*. 2012;4:165rv13–rv13.
- [5]. Maghrabi F, Denning DW. The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach. *Current fungal infection reports*. 2017;11:242–51. [PubMed: 29213345]
- [6]. Benedict K, Richardson M, Vallabhaneni S, Jackson BR, Chiller T. Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks. *The Lancet Infectious diseases*. 2017;17:e403–e11. [PubMed: 28774697]
- [7]. Jackson BR, Beer KD, Chiller T, Benedict K. Estimation of Direct Healthcare Costs of Fungal Diseases in the United States. 2018.
- [8]. Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender NP, Chiller TM, et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. *The Lancet Infectious diseases*. 2017;17:873–81. [PubMed: 28483415]
- [9]. Lin S-J, Schranz J, Teutsch SM. Aspergillosis Case-Fatality Rate: Systematic Review of the Literature. *Clinical Infectious Diseases*. 2001;32:358–66. [PubMed: 11170942]
- [10]. Neville BA, d'Enfert C, Bournoux M-E. *Candida albicans* commensalism in the gastrointestinal tract. *FEMS Yeast Research*. 2015;15:fov081–fov. [PubMed: 26347504]
- [11]. Polvi EJ, Li X, O'Meara TR, Leach MD, Cowen LE. Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies. *Cellular and Molecular Life Sciences*. 2015;72:2261–87. [PubMed: 25700837]
- [12]. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. Persistent *Cryptococcus neoformans* pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. *Infection and immunity*. 2000;68:832–8. [PubMed: 10639453]
- [13]. Maziarz EK, Perfect JR. Cryptococcosis. *Infectious Disease Clinics of North America*. 2016;30:179–206. [PubMed: 26897067]
- [14]. Ok AA, O'zdemir BH, Kimap M, Yilmaz Akcay E, Akar Ozkan E, Haberal M. Invasive fungal infections in liver transplant recipients. *Exp Clin Transplant*. 2014;12:110–6. [PubMed: 24635806]

- [15]. Baddley JW, Schain DC, Gupte AA, Lodhi SA, Kayler LK, Frade JP, et al. Transmission of *Cryptococcus neoformans* by Organ Transplantation. *Clin Infect Dis*. 2011;52:e94–e8. [PubMed: 21220771]
- [16]. Sil A, Andrianopoulos A. Thermally Dimorphic Human Fungal Pathogens--Polyphyletic Pathogens with a Convergent Pathogenicity Trait. *Cold Spring Harbor perspectives in medicine*. 2014;5:a019794–a. [PubMed: 25384771]
- [17]. Paulussen C, Hallsworth JE, Álvarez-Pérez S, Nierman WC, Hamill PG, Blain D, et al. Ecology of aspergillosis: insights into the pathogenic potency of *Aspergillus fumigatus* and some other *Aspergillus* species. *Microbial biotechnology*. 2017;10:296–322. [PubMed: 27273822]
- [18]. Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, et al. Molecular identification of *Aspergillus* species collected for the Transplant-Associated Infection Surveillance Network. *Journal of clinical microbiology*. 2009;47:3138–41. [PubMed: 19675215]
- [19]. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, et al. The Impact of Culture Isolation of *Aspergillus* Species: A Hospital-Based Survey of Aspergillosis. *Clinical Infectious Diseases*. 2001;33:1824–33. [PubMed: 11692293]
- [20]. Araujo R, Rodrigues AG. Variability of germinative potential among pathogenic species of *Aspergillus*. *Journal of clinical microbiology*. 2004;42:4335–7. [PubMed: 15365039]
- [21]. Kozakiewicz Z, Smith D. Physiology of *Aspergillus* In: Smith JE, editor. *Biotechnology handbooks - 7: Aspergillus*. New York: Plenum Press; 1994 p. 23–40.
- [22]. Kwon-Chung KJ, Sugui JA. *Aspergillus fumigatus*--what makes the species a ubiquitous human fungal pathogen? *PLoS pathogens*. 2013;9:e1003743–e. [PubMed: 24348239]
- [23]. Brown NA, Goldman GH. The contribution of *Aspergillus fumigatus* stress responses to virulence and antifungal resistance. *Journal of Microbiology*. 2016;54:243–53.
- [24]. Kowalski CH, Beattie SR, Fuller KK, McGurk EA, Tang Y-W, Hohl TM, et al. Heterogeneity among Isolates Reveals that Fitness in Low Oxygen Correlates with *Aspergillus fumigatus* Virulence. *mBio*. 2016;7:e01515–16. [PubMed: 27651366]
- [25]. Hartmann T, Sasse C, Schedler A, Hasenberg M, Gunzer M, Krappmann S. Shaping the fungal adaptome – Stress responses of *Aspergillus fumigatus*. *International Journal of Medical Microbiology*. 2011;301:408–16. [PubMed: 21565548]
- [26]. Beattie SR, Mark KMK, Thammahong A, Ries LNA, Dhingra S, Caffrey-Carr AK, et al. Filamentous fungal carbon catabolite repression supports metabolic plasticity and stress responses essential for disease progression. *PLoS pathogens*. 2017;13:e1006340–e. [PubMed: 28423062]
- [27]. Willger SD, Grahl N, Cramer RA Jr. *Aspergillus fumigatus* metabolism: clues to mechanisms of in vivo fungal growth and virulence. *Medical mycology*. 2009;47 Suppl 1:S72–S9. [PubMed: 19253141]
- [28]. Frías-De León MG, Zavala-Ramírez M, Córdoba S, Zúñiga G, Duarte-Escalante E, Pérez-Torres A, et al. Phenotypic characteristics of isolates of *Aspergillus* section *Fumigati* from different geographic origins and their relationships with genotypic characteristics. *BMC infectious diseases*. 2011;11:116–. [PubMed: 21554728]
- [29]. Bultman KM, Kowalski CH, Cramer RA. *Aspergillus fumigatus* virulence through the lens of transcription factors. *Medical mycology*. 2017;55:24–38. [PubMed: 27816905]
- [30]. Ries LNA, Beattie S, Cramer RA, Goldman GH. Overview of carbon and nitrogen catabolite metabolism in the virulence of human pathogenic fungi. *Molecular microbiology*. 2018;107:277–97. [PubMed: 29197127]
- [31]. Fröhlich-Nowoisky J, Pickersgill DA, Després VR, Pöschl U. High diversity of fungi in air particulate matter. *Proceedings of the National Academy of Sciences*. 2009;106:12814–9.
- [32]. Mousavi B, Hedayati MT, Hedayati N, Ilkit M, Syedmousavi S. *Aspergillus* species in indoor environments and their possible occupational and public health hazards. *Current medical mycology*. 2016;2:36–42. [PubMed: 28681011]
- [33]. Hansen D, Blahout B, Benner D, Popp W. Environmental sampling of particulate matter and fungal spores during demolition of a building on a hospital area. *Journal of Hospital Infection*. 2008;70:259–64. [PubMed: 18783848]

- [34]. Pilmis B, Thepot-Seegers V, Angebault C, Weiss E, Alaabouche I, Bougnoux ME, et al. Could we predict airborne *Aspergillus* contamination during construction work? *American Journal of Infection Control*. 2017;45:39–41. [PubMed: 27665035]
- [35]. Poole CJM, Wong M. Allergic bronchopulmonary aspergillosis in garden waste (compost) collectors—occupational implications. *Occupational Medicine*. 2013;63:517–9. [PubMed: 23975883]
- [36]. Cafarchia C, Camarda A, Iatta R, Danesi P, Favuzzi V, Di Paola G, et al. Environmental contamination by *Aspergillus* spp. in laying hen farms and associated health risks for farm workers. *Journal of medical microbiology*. 2014;63:464–70. [PubMed: 24430250]
- [37]. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged Granulocytopenia: The Major Risk Factor for Invasive Pulmonary Aspergillosis in Patients with Acute Leukemia. *Ann Intern Med*. 1984;100:345–51. [PubMed: 6696356]
- [38]. King J, Henriet SSV, Warris A. Aspergillosis in Chronic Granulomatous Disease. *Journal of fungi (Basel, Switzerland)*. 2016;2:15.
- [39]. Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. *Thorax*. 2015;70:270–7. [PubMed: 25354514]
- [40]. Patterson KC, Strek ME. Diagnosis and Treatment of Pulmonary Aspergillosis Syndromes. *CHEST*. 2014;146:1358–68. [PubMed: 25367472]
- [41]. Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. *Clinical & developmental immunology*. 2011;2011:843763-. [PubMed: 21603163]
- [42]. Kraemer R, Deloséa N, Ballinari P, Gallati S, Cramer R. Effect of Allergic Bronchopulmonary Aspergillosis on Lung Function in Children with Cystic Fibrosis. *Am J Respir Crit Care Med*. 2006;174:1211–20. [PubMed: 16959918]
- [43]. Lass-Flörl C, Salzer GM, Schmid T, Rabl W, Ulmer H, Dierich MP. Pulmonary *Aspergillus* colonization in humans and its impact on management of critically ill patients. *British Journal of Haematology*. 1999;104:745–7. [PubMed: 10192435]
- [44]. Barberán J, García-Pérez F-J, Villena V, Fernández-Villar A, Malmierca E, Salas C, et al. Development of Aspergillosis in a cohort of non-neutropenic, non-transplant patients colonised by *Aspergillus* spp. *BMC infectious diseases*. 2017;17:34-. [PubMed: 28056830]
- [45]. Garcia-Vidal C, Peghin M, Cervera C, Gudiol C, Ruiz-Camps I, Moreno A, et al. Causes of death in a contemporary cohort of patients with invasive aspergillosis. *PloS one*. 2015;10:e0120370-e. [PubMed: 25803853]
- [46]. Tashiro T, Kakeya H, Yamamoto K, Seki M, Tashiro M, Kohno S, et al. Diagnostic significance of *Aspergillus* species isolated from respiratory samples in an adult pneumology ward. *Medical Mycology*. 2011;49:581–7. [PubMed: 21208028]
- [47]. Shahi M, Ayatollahi Mousavi SA, Nabili M, Aliyali M, Khodavaisy S, Badali H. *Aspergillus* colonization in patients with chronic obstructive pulmonary disease. *Current medical mycology*. 2015;1:45–51. [PubMed: 28680996]
- [48]. Delhaes L, Monchy S, Fréalle E, Hubans C, Salleron J, Leroy S, et al. The Airway Microbiota in Cystic Fibrosis: A Complex Fungal and Bacterial Community—Implications for Therapeutic Management. *PLoS One*. 2012;7:e36313. [PubMed: 22558432]
- [49]. Williams C, Ranjendran R, Ramage G. Pathogenesis of Fungal Infections in Cystic Fibrosis. *Current Fungal Infection Reports*. 2016;10:163–9. [PubMed: 28035247]
- [50]. Kramer R, Sauer-Heilborn A, Welte T, Guzman CA, Abraham W-R, Höfle MG. Cohort Study of Airway Mycobiome in Adult Cystic Fibrosis Patients: Differences in Community Structure between Fungi and Bacteria Reveal Predominance of Transient Fungal Elements. *Journal of Clinical Microbiology*. 2015;53:2900–7. [PubMed: 26135861]
- [51]. Reece E, Segurado R, Jackson A, McClean S, Renwick J, Greally P. Co-colonisation with *Aspergillus fumigatus* and *Pseudomonas aeruginosa* is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. *BMC pulmonary medicine*. 2017;17:70-. [PubMed: 28431569]
- [52]. Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, et al. Lung microbiota across age and disease stage in cystic fibrosis. *Scientific reports*. 2015;5:10241-. [PubMed: 25974282]

- [53]. May RC, Stone NRH, Wiesner DL, Bicanic T, Nielsen K. Cryptococcus: from environmental saprophyte to global pathogen. *Nature reviews Microbiology*. 2016;14:106–17. [PubMed: 26685750]
- [54]. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain. *Memórias do Instituto Oswaldo Cruz*. 2018;113.
- [55]. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L-a, Niang R, et al. Serologic Evidence for *Cryptococcus neoformans* Infection in Early Childhood. *Pediatrics*. 2001;107:e66–e. [PubMed: 11331716]
- [56]. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. *Cryptococcus neoformans* and *Cryptococcus gattii*, the etiologic agents of cryptococcosis. *Cold Spring Harbor perspectives in medicine*. 2014;4:a019760–a. [PubMed: 24985132]
- [57]. Ellis DH, Pfeiffer TJ. Natural habitat of *Cryptococcus neoformans* var. *gattii*. *Journal of clinical microbiology*. 1990;28:1642–4. [PubMed: 2199524]
- [58]. Johnston SA, Voelz K, May RC. *Cryptococcus neoformans* Thermotolerance to Avian Body Temperature Is Sufficient For Extracellular Growth But Not Intracellular Survival In Macrophages. *Scientific Reports*. 2016;6:20977. [PubMed: 26883088]
- [59]. Chen SCA, Meyer W, Sorrell TC. *Cryptococcus gattii* infections. *Clinical microbiology reviews*. 2014;27:980–1024. [PubMed: 25278580]
- [60]. Schmertmann LJ, Kan A, Mella VSA, Fernandez CM, Crowther MS, Madani G, et al. Prevalence of cryptococcal antigenemia and nasal colonization in a free-ranging koala population. 2019.
- [61]. Dixit A, Carroll SF, Qureshi ST. *Cryptococcus gattii*: An Emerging Cause of Fungal Disease in North America *Journal of Interdisciplinary Perspectives on Infectious Diseases*. 2009;2009:13.
- [62]. Chen SC, Meyer W, Sorrell TC. *Cryptococcus gattii* infections. *Clin Microbiol Rev*. 2014;27:980–1024. [PubMed: 25278580]
- [63]. Klinkenberg B, Acheson ES, Mak S, Galanis E, Bartlett K. Searching for clues for eighteen years: Deciphering the ecological determinants of *Cryptococcus gattii* on Vancouver Island, British Columbia. *Medical Mycology*. 2017;56:129–44.
- [64]. Byrnes EJ III, Li W, Lewit Y, Ma H, Voelz K, Ren P, et al. Emergence and Pathogenicity of Highly Virulent *Cryptococcus gattii* Genotypes in the Northwest United States. *PLOS Pathogens*. 2010;6:e1000850. [PubMed: 20421942]
- [65]. Elsegeiny W, Marr KA, Williamson PR. Immunology of Cryptococcal Infections: Developing a Rational Approach to Patient Therapy. *Frontiers in immunology*. 2018;9:651-. [PubMed: 29670625]
- [66]. Ngamskulrungron P, Chang Y, Sionov E, Kwon-Chung KJ. The Primary Target Organ of *Cryptococcus gattii* Is Different from That of *Cryptococcus neoformans* in a Murine Model. 2012;3:e00103–12.
- [67]. Chen J, Varma A, Diaz MR, Litvintseva A,P, Wollenberg K,K, Kwon-Chung K,J. *Cryptococcus neoformans* Strains and Infection in Apparently Immunocompetent Patients, China. *Emerging Infectious Disease journal*. 2008;14:755.
- [68]. Henao-Martínez AF, Gross L, McNair B, McCollister B, DeSanto K, Montoya JG, et al. Risk Factors for Cryptococcal Meningitis: A Single United States Center Experience. *Mycopathologia*. 2016;181:807–14. [PubMed: 27502502]
- [69]. Maskarinec SA, Johnson MD, Perfect JR. Genetic Susceptibility to Fungal Infections: What is in the Genes? *Curr Clin Microbiol Rep*. 2016;3:81–91. [PubMed: 27547700]
- [70]. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kiertiburanakul S, Shaw PA, et al. Adult-Onset Immunodeficiency in Thailand and Taiwan. 2012;367:725–34.
- [71]. Saijo T, Chen J, Chen SC-A, Rosen LB, Yi J, Sorrell TC, et al. Anti-Granulocyte- Macrophage Colony-Stimulating Factor Autoantibodies Are a Risk Factor for Central Nervous System Infection by *Cryptococcus gattii* in Otherwise Immunocompetent Patients. 2014;5:e00912–14.
- [72]. Rohatgi S, Gohil S, Kuniholm MH, Schultz H, Dufaud C, Armour KL, et al. Fc Gamma Receptor 3A Polymorphism and Risk for HIV-Associated Cryptococcal Disease. 2013;4:e00573–13.
- [73]. Hu X-P, Wu J-Q, Zhu L-P, Wang X, Xu B, Wang R-Y, et al. Association of Fc γ Receptor IIB Polymorphism with Cryptococcal Meningitis in HIV-Uninfected Chinese Patients. *PLOS ONE*. 2012;7:e42439. [PubMed: 22879986]

- [74]. Xu B, Wu J-Q, Zhu L-P, Guan M, Weng X-H, Hu X-P, et al. Genotypes Coding for Mannose-Binding Lectin Deficiency Correlated With Cryptococcal Meningitis in HIV-Uninfected Chinese Patients. *The Journal of Infectious Diseases*. 2011;203:1686–91. [PubMed: 21592999]
- [75]. Jirapongsananuruk O, Luangwedchakarn V, Niemela JE, Pacharn P, Visitsunthorn N, Thepthai C, et al. Cryptococcal osteomyelitis in a child with a novel compound mutation of the IL12RB1 gene. *Asian Pac J Allergy Immunol*. 2012;30:79–82. [PubMed: 22523911]
- [76]. Bahr NC, Antinori S, Wheat LJ, Sarosi GA. Histoplasmosis infections worldwide: thinking outside of the Ohio River valley. *Curr Trop Med Rep*. 2015;2:70–80. [PubMed: 26279969]
- [77]. Manos NE, Ferebee SH, Kerschbaum WF. Geographic Variation in the Prevalence of Histoplasmin Sensitivity. *CHEST*. 1956;29:649–68.
- [78]. Kauffman CA. Histoplasmosis: a Clinical and Laboratory Update. *Clinical Microbiology Reviews*. 2007;20:115–32. [PubMed: 17223625]
- [79]. Diaz JH. Environmental and Wilderness-Related Risk Factors for Histoplasmosis: More Than Bats in Caves. *Wilderness & Environmental Medicine*. 2018;29:531–40. [PubMed: 30266238]
- [80]. Mochi A, Edwards PQ. Geographical distribution of histoplasmosis and histoplasmin sensitivity. *Bulletin of the World Health Organization*. 1952;5:259–91. [PubMed: 14935779]
- [81]. Armstrong PA, Jackson BR, Haselow D, Fields V, Ireland M, Austin C, et al. Multistate Epidemiology of Histoplasmosis, United States, 2011–2014. *Emerging infectious diseases*. 2018;24:425–31. [PubMed: 29460731]
- [82]. Randhawa HS. Occurrence of histoplasmosis in Asia. *Mycopathol Mycol Appl*. 1970;41:75–89. [PubMed: 4938836]
- [83]. Pan B, Chen M, Pan W, Liao W. Histoplasmosis: a new endemic fungal infection in China? Review and analysis of cases. *Mycoses*. 2013;56:212–21. [PubMed: 23216676]
- [84]. McLeod DSA, Mortimer RH, Perry-Keene DA, Allworth A, Woods ML, Perry-Keene J, et al. Histoplasmosis in Australia: Report of 16 Cases and Literature Review. *Medicine*. 2011;90:61–8. [PubMed: 21200187]
- [85]. Pierre L, Frédéric B, Véronique B, Jacques C, Patricia M-K, Bertrand D, et al. Literature Review and Case Histories of *Histoplasma capsulatum* var. *duboisii* Infections in HIV-infected Patients. *Emerging Infectious Disease journal*. 2007;13:1647.
- [86]. Darre T, Saka B, Mouhari-Tour A, Dorkenoo AM, Koffi A, Pitche VP, et al. Histoplasmosis by *Histoplasma capsulatum* var. *duboisii* Observed at the Laboratory of Pathological Anatomy of Lome in Togo. *Journal of Pathogens*. 2017;2017:3.
- [87]. Benedict K, Mody RK. Epidemiology of Histoplasmosis Outbreaks, United States, 1938–2013. *Emerging infectious diseases*. 2016;22:370–8. [PubMed: 26890817]
- [88]. Hoff GL, Bigler WJ. The role of bats in the propagation and spread of histoplasmosis: a review. *Journal of Wildlife Diseases*. 1981;17:191–6. [PubMed: 7017172]
- [89]. Carter DA, Burt A, Taylor JW, Koenig GL, White TJ. Clinical isolates of *Histoplasma capsulatum* from Indianapolis, Indiana, have a recombining population structure. *Journal of clinical microbiology*. 1996;34:2577–84. [PubMed: 8880523]
- [90]. Kasuga T, White TJ, Koenig G, McEwen J, Restrepo A, Castañeda E, et al. Phylogeography of the fungal pathogen *Histoplasma capsulatum*. *Molecular Ecology*. 2003;12:3383–401. [PubMed: 14629354]
- [91]. Muniz MdM, Morais E Silva Tavares P, Meyer W, Nosanchuk JD, Zancoppe-Oliveira RM. Comparison of different DNA-based methods for molecular typing of *Histoplasma capsulatum*. *Applied and environmental microbiology*. 2010;76:4438–47. [PubMed: 20453140]
- [92]. Damasceno LS, Leitao TM, Taylor ML, Muniz MM, Zancoppe-Oliveira RM. The use of genetic markers in the molecular epidemiology of histoplasmosis: a systematic review. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology*. 2016;35:19–27.
- [93]. Sepúlveda VE, Márquez R, Turissini DA, Goldman WE, Matute DR. Genome Sequences Reveal Cryptic Speciation in the Human Pathogen *Histoplasma capsulatum*. *mBio*. 2017;8:e01339–17. [PubMed: 29208741]
- [94]. Azar MM, Hage CA. Clinical Perspectives in the Diagnosis and Management of Histoplasmosis. *Clin Chest Med*. 2017;38:403–15. [PubMed: 28797485]

- [95]. Deepe GS Jr., Gibbons RS. T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with *Histoplasma capsulatum*. *The Journal of infectious diseases*. 2006;193:322–30. [PubMed: 16362898]
- [96]. Straub M, Schwarz J. The healed primary complex in histoplasmosis. *American journal of clinical pathology*. 1955;25:727–41. [PubMed: 14387973]
- [97]. Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. *Nature Reviews Microbiology*. 2006;5:13. [PubMed: 17160002]
- [98]. Kadaria D, Archie DS, SultanAli I, Weiman DS, Freire AX, Zaman MK. Dual time point positron emission tomography/computed tomography scan in evaluation of intrathoracic lesions in an area endemic for histoplasmosis and with high prevalence of sarcoidosis. *The American journal of the medical sciences*. 2013;346:358–62. [PubMed: 23276900]
- [99]. Wheat LJ, Connolly-Stringfield PA, Baker RL, Curfman MF, Eads ME, Israel KS, et al. Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature. *Medicine (Baltimore)*. 1990;69:361–74. [PubMed: 2233233]
- [100]. Zanotti P, Chirico C, Gulletta M, Ardighieri L, Casari S, Roldan EQ, et al. Disseminated Histoplasmosis as AIDS-presentation. Case Report and Comprehensive Review of Current Literature. *Mediterranean journal of hematology and infectious diseases*. 2018;10:e2018040. [PubMed: 30002796]
- [101]. Adenis AA, Aznar C, Couppié P. Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. *Curr Trop Med Rep* 2014 p. 119–28. [PubMed: 24860719]
- [102]. Benedict K, Derado G, Mody RK. Histoplasmosis-Associated Hospitalizations in the United States, 2001–2012. *Open Forum Infectious Diseases*. 2016;3:ofv219–ofv. [PubMed: 26894201]
- [103]. Kauffman CA, Freifeld AG, Andes DR, Baddley JW, Herwaldt L, Walker RC, et al. Endemic fungal infections in solid organ and hematopoietic cell transplant recipients enrolled in the Transplant-Associated Infection Surveillance Network (TRANSNET). *Transplant infectious disease: an official journal of the Transplantation Society*. 2014;16:213–24. [PubMed: 24589027]
- [104]. Assi M, Martin S, Wheat LJ, Hage C, Freifeld A, Avery R, et al. Histoplasmosis After Solid Organ Transplant. *Clinical Infectious Diseases*. 2013;57:1542–9. [PubMed: 24046304]
- [105]. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker Therapy. *Clinical Infectious Diseases*. 2010;50:85–92. [PubMed: 19951231]
- [106]. Vergidis P, Avery RK, Wheat LJ, Dotson JL, Assi MA, Antoun SA, et al. Histoplasmosis Complicating Tumor Necrosis Factor- α Blocker Therapy: A Retrospective Analysis of 98 Cases. *Clinical Infectious Diseases*. 2015;61:409–17. [PubMed: 25870331]
- [107]. Taylor ML, Perez-Mejia A, Yamamoto-Furusho JK, Granados J. Immunologic, genetic and social human risk factors associated to histoplasmosis: studies in the State of Guerrero, Mexico. *Mycopathologia*. 1997;138:137–42. [PubMed: 9468664]
- [108]. Zerbe CS, Holland SM. Disseminated Histoplasmosis in Persons with Interferon- γ Receptor 1 Deficiency. *Clinical Infectious Diseases*. 2005;41:38–41.
- [109]. McBride JA, Gauthier GM, Klein BS. Clinical Manifestations and Treatment of Blastomycosis. *Clinics in chest medicine*. 2017;38:435–49. [PubMed: 28797487]
- [110]. Saccente M, Woods GL. Clinical and Laboratory Update on Blastomycosis. *Clinical Microbiology Reviews*. 2010;23:367–81. [PubMed: 20375357]
- [111]. Schwartz IS, Wiederhold NP, Hanson KE, Patterson TF, Sigler L. *Blastomyces helicus*, a New Dimorphic Fungus Causing Fatal Pulmonary and Systemic Disease in Humans and Animals in Western Canada and the United States. *Clinical Infectious Diseases*. 2019;68:188–95. [PubMed: 29878145]
- [112]. Baily GG, Robertson VJ, Neill P, Garrido P, Levy LF. Blastomycosis in Africa: Clinical Features, Diagnosis, and Treatment. *Reviews of Infectious Diseases*. 1991;13:1005–8. [PubMed: 1962074]
- [113]. Randhawa HS, Chowdhary A, Kathuria S, Roy P, Misra DS, Jain S, et al. Blastomycosis in India: report of an imported case and current status. *Medical Mycology*. 2013;51:185–92. [PubMed: 22646243]

- [114]. McTaggart LR, Brown EM, Richardson SE. Phylogeographic Analysis of *Blastomyces dermatitidis* and *Blastomyces gilchristii* Reveals an Association with North American Freshwater Drainage Basins. *PLOS ONE*. 2016;11:e0159396. [PubMed: 27428521]
- [115]. Klein BS, Vergeront JM, Weeks RJ, Kumar UN, Mathai G, Varkey B, et al. Isolation of *Blastomyces dermatitidis* in Soil Associated with a Large Outbreak of Blastomycosis in Wisconsin. *New England Journal of Medicine*. 1986;314:529–34. [PubMed: 3945290]
- [116]. Davies JL, Epp T, Burgess HJ. Prevalence and geographic distribution of canine and feline blastomycosis in the Canadian prairies. *The Canadian veterinary journal = La revue veterinaire canadienne*. 2013;54:753–60. [PubMed: 24155475]
- [117]. Nemeth NM, Campbell GD, Oesterle PT, Shirose L, McEwen B, Jardine CM. Red Fox as Sentinel for *Blastomyces dermatitidis*, Ontario, Canada. *Emerging infectious diseases*. 2016;22:1275–7. [PubMed: 27314650]
- [118]. Morris SK, Brophy J, Richardson SE, Summerbell R, Parkin PC, Jamieson F, et al. Blastomycosis in Ontario, 1994–2003. *Emerging infectious diseases*. 2006;12:274–9. [PubMed: 16494754]
- [119]. Baumgardner DJ, Buggy BP, Mattson BJ, Burdick JS, Ludwig D. Epidemiology of blastomycosis in a region of high endemicity in north central Wisconsin. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 1992;15:629–35. [PubMed: 1420675]
- [120]. Klein BS, Vergeront JM, Disalvo AF, Kaufman L, Davis JP. Two Outbreaks of Blastomycosis Along Rivers in Wisconsin: Isolation of *Blastomyces dermatitidis* from Riverbank Soil and Evidence of its Transmission Along Waterways. *American Review of Respiratory Disease*. 1987;136:1333–8. [PubMed: 3688635]
- [121]. Chapman SW, Lin AC, Hendricks KA, Nolan RL, Currier MM, Morris KR, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. *Seminars in respiratory infections*. 1997;12:219–28. [PubMed: 9313293]
- [122]. Bradsher RW. Histoplasmosis and blastomycosis. *Clin Infect Dis*. 1996;22 Suppl 2:S102–11. [PubMed: 8722836]
- [123]. Kralt D, Light B, Cheang M, MacNair T, Wiebe L, Limerick B, et al. Clinical characteristics and outcomes in patients with pulmonary blastomycosis. *Mycopathologia*. 2009;167:115–24. [PubMed: 18931937]
- [124]. Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: Presentation of nine cases and review of the literature. *Annals of Diagnostic Pathology*. 2001;5:1–9. [PubMed: 11172200]
- [125]. Vasquez JE, Mehta JB, Agrawal R, Sarubbi FA. Blastomycosis in northeast Tennessee. *Chest*. 1998;114:436–43. [PubMed: 9726727]
- [126]. Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. *N Engl J Med*. 1993;329:1231–6. [PubMed: 8413389]
- [127]. Cherniss EI, Waisbren BA. North American blastomycosis: a clinical study of 40 cases. *Ann Intern Med*. 1956;44:105–23. [PubMed: 13275854]
- [128]. Duttera MJ Jr., Osterhout S. North American blastomycosis: a survey of 63 cases. *Southern medical journal*. 1969;62:295–301. [PubMed: 4885288]
- [129]. Gauthier GM, Safdar N, Klein BS, Andes DR. Blastomycosis in solid organ transplant recipients. *Transplant Infectious Disease*. 2007;9:310–7. [PubMed: 17428278]
- [130]. Pappas PG, Pottage JC, Powderly WG, Fraser VJ, Stratton CW, McKenzie S, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. *Ann Intern Med*. 1992;116:847–53. [PubMed: 1567099]
- [131]. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. *Drugs*. 2009;69:1403–15. [PubMed: 19634920]
- [132]. Smith RJ, Boos MD, Burnham JM, McKay EM, Kim J, Jen M. Atypical Cutaneous Blastomycosis in a Child With Juvenile Idiopathic Arthritis on Infliximab. *Pediatrics*. 2015;136:e1386–9. [PubMed: 26482671]

- [133]. Klein BS, Bradsher RW, Vergeront JM, Davis JP. Development of long-term specific cellular immunity after acute *Blastomyces dermatitidis* infection: assessments following a large point-source outbreak in Wisconsin. *J Infect Dis*. 1990;161:97–101. [PubMed: 2295863]
- [134]. Cutler JE, Deepe GS Jr., Klein BS. Advances in combating fungal diseases: vaccines on the threshold. *Nat Rev Microbiol*. 2007;5:13–28. [PubMed: 17160002]
- [135]. Finkel-Jimenez B, Wüthrich M, Brandhorst T, Klein BS. The WI-1 Adhesin Blocks Phagocyte TNF- α Production, Imparting Pathogenicity on *Blastomyces dermatitidis*. *The Journal of Immunology*. 2001;166:2665. [PubMed: 11160330]
- [136]. Teixeira MM, Barker BM. Use of Population Genetics to Assess the Ecology, Evolution, and Population Structure of *Coccidioides*. *Emerging infectious diseases*. 2016;22:1022–30. [PubMed: 27191589]
- [137]. Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, et al. Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. *Clinical microbiology reviews*. 2013;26:505–25. [PubMed: 23824371]
- [138]. Petersen LR, Marshall SL, Barton-Dickson C, Hajjeh RA, Lindsley MD, Warnock DW, et al. Coccidioidomycosis among workers at an archeological site, northeastern Utah. *Emerging infectious diseases*. 2004;10:637–42. [PubMed: 15200853]
- [139]. Litvintseva AP, Marsden-Haug N, Hurst S, Hill H, Gade L, Driebe EM, et al. Valley fever: finding new places for an old disease: *Coccidioides immitis* found in Washington State soil associated with recent human infection. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2015;60:e1–e3. [PubMed: 25165087]
- [140]. Lockhart SR, McCotter OZ, Chiller TM. Emerging Fungal Infections in the Pacific Northwest: The Unrecognized Burden and Geographic Range of *Cryptococcus gattii* and *Coccidioides immitis*. *Microbiology Spectrum*. 2016;4.
- [141]. Fisher FS, Bultman MW, Johnson SM, Pappagianis D, Zaborsky E. *Coccidioides* niches and habitat parameters in the southwestern United States: a matter of scale. *Annals of the New York Academy of Sciences*. 2007;1111:47–72. [PubMed: 17344527]
- [142]. Einstein HE, Johnson RH. Coccidioidomycosis: New Aspects of Epidemiology and Therapy. *Clinical Infectious Diseases*. 1993;16:349–56. [PubMed: 8452945]
- [143]. del Rocio Reyes-Montes M, Pérez-Huitrón MA, Ocaña-Monroy JL, Frías-De-León MG, Martínez-Herrera E, Arenas R, et al. The habitat of *Coccidioides* spp. and the role of animals as reservoirs and disseminators in nature. *BMC Infectious Diseases*. 2016;16:550. [PubMed: 27724885]
- [144]. Egeberg RO, Elconin AE, Egeberg MC. Effect of salinity and temperature on *Coccidioides immitis* and three antagonistic soil saprophytes. *Journal of bacteriology*. 1964;88:473–6. [PubMed: 14203366]
- [145]. Baumgardner DJ. Soil-Related Bacterial and Fungal Infections. *The Journal of the American Board of Family Medicine*. 2012;25:734. [PubMed: 22956709]
- [146]. Lacy GH, Swatek FE. Soil ecology of *Coccidioides immitis* at Amerindian middens in California. *Applied microbiology*. 1974;27:379–88. [PubMed: 4856715]
- [147]. Emmons CW. Coccidioidomycosis in Wild Rodents. A Method of Determining the Extent of Endemic Areas. *Public Health Reports (1896–1970)*. 1943;58:1–5.
- [148]. Maddy K Establishment of coccidioides immitis in negative soil following burial of infected animals and animal tissues In: Ajello L, editor. *Papers from the Second Symposium on Coccidioidomycosis Tuscon, AZ: University of Arizona Press; 1967 p. 309–12.*
- [149]. Brown J, Benedict K, Park BJ, Thompson GR 3rd. Coccidioidomycosis: epidemiology. *Clinical epidemiology*. 2013;5:185–97. [PubMed: 23843703]
- [150]. Sharpton TJ, Stajich JE, Rounsley SD, Gardner MJ, Wortman JR, Jordar VS, et al. Comparative genomic analyses of the human fungal pathogens *Coccidioides* and their relatives. *Genome Research*. 2009;19:1722–31. [PubMed: 19717792]
- [151]. Barker BM, Tabor JA, Shubitz LF, Perrill R, Orbach MJ. Detection and phylogenetic analysis of *Coccidioides posadasii* in Arizona soil samples. *Fungal Ecology*. 2012;5:163–76.

- [152]. Bowers JR, Parise KL, Kelley EJ, Lemmer D, Schupp JM, Driebe EM, et al. Direct detection of *Coccidioides* from Arizona soils using CoccENV, a highly sensitive and specific real-time PCR assay. *Medical Mycology*. 2019;57:246–55. [PubMed: 29534236]
- [153]. Tamerius JD, Comrie AC. *Coccidioidomycosis* Incidence in Arizona Predicted by Seasonal Precipitation. *PLOS ONE*. 2011;6:e21009. [PubMed: 21701590]
- [154]. Kolivras KN, Comrie AC. Modeling valley fever (*coccidioidomycosis*) incidence on the basis of climate conditions. *Int J Biometeorol*. 2003;47:87–101. [PubMed: 12647095]
- [155]. Flynn NM, Hoepfich PD, Kawachi MM, Lee KK, Lawrence RM, Goldstein E, et al. An Unusual Outbreak of Windborne *Coccidioidomycosis*. *New England Journal of Medicine*. 1979;301:358–61. [PubMed: 460324]
- [156]. Talamantes J, Behseta S, Zender CS. Fluctuations in climate and incidence of *coccidioidomycosis* in Kern County, California: a review. *Annals of the New York Academy of Sciences*. 2007;1111:73–82. [PubMed: 17347336]
- [157]. Pappagianis D, Einstein H. Tempest from Tehachapi takes toll on *Coccidioides* conveyed aloft and afar. *The Western journal of medicine*. 1978;129:527–30. [PubMed: 735056]
- [158]. Wack EE, Ampel NM, Sunenshine RH, Galgiani JN. The Return of Delayed-Type Hypersensitivity Skin Testing for *Coccidioidomycosis*. *Clinical Infectious Diseases*. 2015;61:787–91. [PubMed: 25979308]
- [159]. Edwards PQ, Palmer CE. Prevalence of sensitivity to coccidioidin, with special reference to specific and nonspecific reactions to coccidioidin and to histoplasmin. *Diseases of the chest*. 1957;31:35–60. [PubMed: 13384171]
- [160]. Kirkland TN, Fierer J. *Coccidioides immitis* and *posadasii*: A review of their biology, genomics, pathogenesis, and host immunity. *Virulence*. 2018;9:1426–35. [PubMed: 30179067]
- [161]. Cooksey GS, Nguyen A, Knutson K, Tabnak F, Benedict K, McCotter O, et al. Notes from the Field: Increase in *Coccidioidomycosis* - California, 2016. *MMWR Morbidity and mortality weekly report*. 2017;66:833–4. [PubMed: 28796756]
- [162]. Wheeler C, Lucas KD, Mohle-Boetani JC. Rates and risk factors for *Coccidioidomycosis* among prison inmates, California, USA, 2011. *Emerging infectious diseases*. 2015;21:70–5. [PubMed: 25533149]
- [163]. Pappagianis D. Epidemiology of *coccidioidomycosis*. *Current topics in medical mycology*. 1988;2:199–238. [PubMed: 3288356]
- [164]. Lisa V, David N, Mark W, Elizabeth L, Timothy F, Donald L, et al. *Coccidioidomycosis* as a Common Cause of Community-acquired Pneumonia. *Emerging Infectious Disease journal*. 2006;12:958.
- [165]. Ampel NM, Dols CL, Galgiani JN. *Coccidioidomycosis* during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. *Am J Med*. 1993;94:235–40. [PubMed: 8095771]
- [166]. Ampel NM. Delayed-type hypersensitivity, in vitro T-cell responsiveness and risk of active *coccidioidomycosis* among HIV-infected patients living in the coccidioidal endemic area. *Medical mycology*. 1999;37:245–50. [PubMed: 10421859]
- [167]. Masannat FY, Ampel NM. *Coccidioidomycosis* in patients with HIV-1 infection in the era of potent antiretroviral therapy. *Clin Infect Dis*. 2010;50:1–7. [PubMed: 19995218]
- [168]. Bronnimann DA, Adam RD, Galgiani JN, Habib MP, Petersen EA, Porter B, et al. *Coccidioidomycosis* in the acquired immunodeficiency syndrome. *Ann Intern Med*. 1987;106:372–9. [PubMed: 3813236]
- [169]. Vikram HR, Blair JE. *Coccidioidomycosis* in transplant recipients: a primer for clinicians in nonendemic areas. *Current opinion in organ transplantation*. 2009;14:606–12. [PubMed: 19812497]
- [170]. Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by *Coccidioides* species. *Current opinion in infectious diseases*. 2008;21:415–20. [PubMed: 18594295]
- [171]. Blair JE. *Coccidioidomycosis* in liver transplantation. *Liver Transplantation*. 2006;12:31–9. [PubMed: 16382459]

- [172]. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists. *Arthritis & Rheumatism*. 2004;50:1959–66. [PubMed: 15188373]
- [173]. Fisher BT, Chiller TM, Prasad PA, Beveridge M, Walsh TJ, Zaoutis TE. Hospitalizations for coccidioidomycosis at forty-one children's hospitals in the United States. *The Pediatric infectious disease journal*. 2010;29:243–7. [PubMed: 19934792]
- [174]. Vinh DC, Masannat F, Dzioba RB, Galgiani JN, Holland SM. Refractory disseminated coccidioidomycosis and mycobacteriosis in interferon-gamma receptor 1 deficiency. *Clin Infect Dis*. 2009;49:e62–5. [PubMed: 19681704]
- [175]. Vinh DC, Schwartz B, Hsu AP, Miranda DJ, Valdez PA, Fink D, et al. Interleukin-12 receptor beta1 deficiency predisposing to disseminated Coccidioidomycosis. *Clin Infect Dis*. 2011;52:e99–e102. [PubMed: 21258095]
- [176]. Sampaio EP, Hsu AP, Pechacek J, Bax HI, Dias DL, Paulson ML, et al. Signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations and disseminated coccidioidomycosis and histoplasmosis. *The Journal of allergy and clinical immunology*. 2013;131:1624–34. [PubMed: 23541320]
- [177]. Odio CD, Marciano BE, Galgiani JN, Holland SM. Risk Factors for Disseminated Coccidioidomycosis, United States. *Emerg Infect Dis*. 2017;23.
- [178]. Crum NF, Lederman ER, Stafford CM, Parrish JS, Wallace MR. Coccidioidomycosis: a descriptive survey of a reemerging disease. *Clinical characteristics and current controversies. Medicine (Baltimore)*. 2004;83:149–75. [PubMed: 15118543]
- [179]. Charalambous LT, Premji A, Tybout C, Hunt A, Cutshaw D, Elsamadicy AA, et al. Prevalence, healthcare resource utilization and overall burden of fungal meningitis in the United States. *Journal of medical microbiology*. 2018;67:215–27. [PubMed: 29244019]
- [180]. Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. *Am J Med*. 2006;119:964–9. [PubMed: 17071165]
- [181]. Bercovitch RS, Catanzaro A, Schwartz BS, Pappagianis D, Watts DH, Ampel NM. Coccidioidomycosis During Pregnancy: A Review and Recommendations for Management. *Clinical Infectious Diseases*. 2011;53:363–8. [PubMed: 21810749]
- [182]. Powell BL, Drutz DJ, Huppert M, Sun SH. Relationship of progesterone- and estradiol-binding proteins in *Coccidioides immitis* to coccidioidal dissemination in pregnancy. *Infection and immunity*. 1983;40:478–85. [PubMed: 6188699]
- [183]. Ruddy BE, Mayer AP, Ko MG, Labonte HR, Borovansky JA, Boroff ES, et al. Coccidioidomycosis in African Americans. *Mayo Clinic proceedings*. 2011;86:63–9. [PubMed: 21193657]
- [184]. Pappagianis D, Lindsay S, Beall S, Williams P. Ethnic background and the clinical course of coccidioidomycosis. *The American review of respiratory disease*. 1979;120:959–61. [PubMed: 507518]
- [185]. Brunet K, Alanio A, Lortholary O, Rammaert B. Reactivation of dormant/latent fungal infection. *The Journal of infection*. 2018;77:463–8. [PubMed: 30417827]
- [186]. Campbell JH, Winter JH, Richardson MD, Shankland GS, Banham SW. Treatment of pulmonary aspergilloma with itraconazole. *Thorax*. 1991;46:839–41. [PubMed: 1663275]
- [187]. De Beule K, De Doncker P, Cauwenbergh G, Koster M, Legendre R, Blatchford N, et al. The Treatment of Aspergillosis and Aspergilloma with Itraconazole, Clinical Results of an Open International Study (1982 – 1987)/Die Behandlung der Aspergillose und des Aspergilloms mit Itraconazol, Klinische Ergebnisse einer offenen internationalen Studie (1982 – 1987). *Mycoses*. 1988;31:476–85. [PubMed: 2849056]
- [188]. Lebeau B, Pelloux H, Pinel C, Michallet M, Goût JP, Pison C, et al. Itraconazole in the treatment of aspergillosis: a study of 16 cases. *Mycoses*. 1994;37:171–9. [PubMed: 7898513]
- [189]. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. *Eur Respir J*. 2011;37:865–72. [PubMed: 20595150]
- [190]. Jhun BW, Jung WJ, Hwang NY, Park HY, Jeon K, Kang E-S, et al. Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. *PloS one*. 2017;12:e0188716–e. [PubMed: 29190796]

- [191]. Hirano K, Yoshida M, Kohno S, Ide S, Tashiro T, Imamura Y, et al. The risk factors for developing of chronic pulmonary aspergillosis in nontuberculous mycobacteria patients and clinical characteristics and outcomes in chronic pulmonary aspergillosis patients coinfecting with nontuberculous mycobacteria. *Med Mycol*. 2016;54:120–7. [PubMed: 26531100]
- [192]. Lee JG, Lee CY, Park IK, Kim DJ, Chang J, Kim SK, et al. Pulmonary aspergilloma: Analysis of prognosis in relation to symptoms and treatment. *The Journal of Thoracic and Cardiovascular Surgery*. 2009;138:820–5. [PubMed: 19660294]
- [193]. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. *Clinical & Experimental Allergy*. 2013;43:850–73. [PubMed: 23889240]
- [194]. Kirsten D, Nowak D, Rabe KF, Magnussen H. [Diagnosis of bronchopulmonary aspergillosis is often made too late]. *Med Klin (Munich)*. 1993;88:353–6. [PubMed: 8336661]
- [195]. Agarwal R, Chakrabarti A. Epidemiology of allergic bronchopulmonary aspergillosis In: Pasqualotto A, editor. *Aspergillosis: From Diagnosis to Prevention*. New York: Springer; 2010 p. 671–88.
- [196]. Zeaske R, Bruns WT, Fink JN, Greenberger PA, Colby H, Liotta JL, et al. Immune responses to *Aspergillus* in cystic fibrosis. *Journal of Allergy and Clinical Immunology*. 1988;82:73–7. [PubMed: 3392373]
- [197]. Janahi IA, Rehman A, Al-Naimi AR. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. *Annals of thoracic medicine*. 2017;12:74–82. [PubMed: 28469716]
- [198]. Muro M, Mondejar-López P, Moya-Quiles MR, Salgado G, Pastor-Vivero MD, Lopez-Hernandez R, et al. HLA-DRB1 and HLA-DQB1 genes on susceptibility to and protection from allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. *Microbiology and Immunology*. 2013;57:193–7. [PubMed: 23278646]
- [199]. Hogaboam CM, Carpenter KJ, Schuh JM, Buckland KF. *Aspergillus* and asthma – any link? *Medical Mycology*. 2005;43:197–202.
- [200]. Richardson JP, Moyes DL. Adaptive immune responses to *Candida albicans* infection. *Virulence*. 2015;6:327–37. [PubMed: 25607781]
- [201]. Blanco JL, Garcia ME. Immune response to fungal infections. *Veterinary Immunology and Immunopathology*. 2008;125:47–70. [PubMed: 18565595]
- [202]. Shibuya K, Hirata A, Omuta J, Sugamata M, Katori S, Saito N, et al. Granuloma and cryptococcosis. *Journal of Infection and Chemotherapy*. 2005;11:115–22. [PubMed: 15990974]
- [203]. Garcia-Hermoso D, Janbon G, Dromer F. Epidemiological evidence for dormant *Cryptococcus neoformans* infection. *Journal of clinical microbiology*. 1999;37:3204–9. [PubMed: 10488178]
- [204]. Salyer WR, Salyer DC, Baker RD. Primary complex of *Cryptococcus* and pulmonary lymph nodes. *J Infect Dis*. 1974;130:74–7. [PubMed: 4834923]
- [205]. Saha DC, Goldman DL, Shao X, Casadevall A, Husain S, Limaye AP, et al. Serologic Evidence for Reactivation of Cryptococcosis in Solid-Organ Transplant Recipients. 2007;14:1550–4.
- [206]. Alanio A, Vernel-Pauillac F, Sturny-Leclère A, Dromer F. *Cryptococcus neoformans* host adaptation: toward biological evidence of dormancy. *mBio*. 2015;6:e02580–14. [PubMed: 25827423]
- [207]. Goldman DL, Bommarito F, Davis J, Shao X, Casadevall A. Enhanced Allergic Inflammation and Airway Responsiveness in Rats with Chronic *Cryptococcus neoformans* Infection: Potential Role for Fungal Pulmonary Infection in the Pathogenesis of Asthma. *The Journal of Infectious Diseases*. 2006;193:1178–86. [PubMed: 16544260]
- [208]. Richaud C, Chandesris M-O, Lanternier F, Benzaquen-Förner H, Garcia-Hermoso D, Picard C, et al. Imported African Histoplasmosis in an Immunocompetent Patient 40 Years after Staying in a Disease-Endemic Area. *The American Journal of Tropical Medicine and Hygiene*. 2014;91:1011–4. [PubMed: 25246691]
- [209]. Addidle M, Pynn J, Skellern P, Kasuga T, Grimwade K. Chronic disseminated histoplasmosis with prolonged latency. *The Journal of infection*. 2010;61:272–4. [PubMed: 20600299]
- [210]. Tseng T-C, Liaw S-J, Hsiao C-H, Wang C-Y, Lee L-N, Huang T-S, et al. Molecular Evidence of Recurrent Histoplasmosis with 9-Year Latency in a Patient with Addison's Disease. *Journal of Clinical Microbiology*. 2005;43:4911–3. [PubMed: 16145175]

- [211]. Desmet P, Vogelaers D, Afschrift M. Progressive disseminated histoplasmosis 10 years after return out of Africa in an immunocompetent host. *Acta Clinica Belgica*. 2004;59:274–8. [PubMed: 15641397]
- [212]. Cuellar-Rodriguez J, Avery RK, Lard M, Budev M, Gordon SM, Shrestha NK, et al. Histoplasmosis in Solid Organ Transplant Recipients: 10 Years of Experience at a Large Transplant Center in an Endemic Area. *Clinical Infectious Diseases*. 2009;49:710–6. [PubMed: 19635026]
- [213]. Gajurel K, Dhakal R, Deresinski S. Histoplasmosis in transplant recipients. *Clinical Transplantation*. 2017;31:e13087.
- [214]. Rubio-Carrasquilla M, Santa CD, Rendón JP, Botero-Garcés J, Moreno E, Cano LE. An interferon gamma release assay specific for *Histoplasma capsulatum* to detect asymptomatic infected individuals: A proof of concept study. *Medical Mycology*. 2018;myy131–myy.
- [215]. Reed KD, Meece JK, Archer JR, Peterson AT. Ecologic niche modeling of *Blastomyces dermatitidis* in Wisconsin. *PloS one*. 2008;3:e2034–e. [PubMed: 18446224]
- [216]. Winquist EW, Walmsley SL, Berinstein NL. Reactivation and dissemination of blastomycosis complicating Hodgkin's disease: a case report and review of the literature. *Am J Hematol*. 1993;43:129–32. [PubMed: 8342540]
- [217]. Blair JE, Logan JL. Coccidioidomycosis in Solid Organ Transplantation. *Clinical Infectious Diseases*. 2001;33:1536–44. [PubMed: 11588699]
- [218]. Arbeloa-Gutierrez L, Kuberski T, Johnson SM, Sagastibelza I, Alaez JI, Pappagianis D. Reactivation of coccidioidomycosis: a prosthetic joint infection in Spain. *European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology*. 2016;35:183–6.
- [219]. Steenbergen JN, Shuman HA, Casadevall A. *Cryptococcus neoformans* interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. *Proceedings of the National Academy of Sciences*. 2001;98:15245.
- [220]. Derengowski LD, Paes HC, Albuquerque P, Tavares AHFP, Fernandes L, Silva-Pereira I, et al. The transcriptional response of *Cryptococcus neoformans* to ingestion by *Acanthamoeba castellanii* and macrophages provides insights into the evolutionary adaptation to the mammalian host. *Eukaryot Cell*. 2013;12:761–74. [PubMed: 23524994]
- [221]. Casadevall A. Amoeba Provide Insight into the Origin of Virulence in Pathogenic Fungi In: Mylonakis E, Ausubel FM, Gilmore M, Casadevall A, editors. *Recent Advances on Model Hosts*. New York, NY: Springer New York; 2012 p. 1–10.
- [222]. Novohradská S, Ferling I, Hillmann F. Exploring Virulence Determinants of Filamentous Fungal Pathogens through Interactions with Soil Amoebae. *Frontiers in cellular and infection microbiology*. 2017;7:497-. [PubMed: 29259922]
- [223]. Wiesner DL, Klein BS. Lung epithelium: barrier immunity to inhaled fungi and driver of fungal-associated allergic asthma. *Current Opinion in Microbiology*. 2017;40:8–13. [PubMed: 29096195]
- [224]. de S Araújo GR, Souza Wd, Frases S. The hidden pathogenic potential of environmental fungi. *Future Microbiology*. 2017;12:1533–40. [PubMed: 29168657]
- [225]. Ene IV, Brunke S, Brown AJP, Hube B. Metabolism in fungal pathogenesis. *Cold Spring Harbor perspectives in medicine*. 4:a019695–a.
- [226]. Drummond RA, Gaffen SL, Hise AG, Brown GD. Innate Defense against Fungal Pathogens. *Cold Spring Harbor perspectives in medicine*. 5:a019620.
- [227]. Fu C, Sun S, Billmyre RB, Roach KC, Heitman J. Unisexual versus bisexual mating in *Cryptococcus neoformans*: Consequences and biological impacts. *Fungal Genetics and Biology*. 2015;78:65–75. [PubMed: 25173822]
- [228]. Giles SS, Dagenais TRT, Botts MR, Keller NP, Hull CM. Elucidating the pathogenesis of spores from the human fungal pathogen *Cryptococcus neoformans*. *Infection and immunity*. 2009;77:3491–500. [PubMed: 19451235]
- [229]. Wang L, Zhai B, Lin X. The Link between Morphotype Transition and Virulence in *Cryptococcus neoformans*. *PLOS Pathogens*. 2012;8:e1002765. [PubMed: 22737071]

- [230]. Filler SG, Sheppard DC. Fungal invasion of normally non-phagocytic host cells. *PLoS pathogens*. 2006;2:e129–e. [PubMed: 17196036]
- [231]. Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. *Curr Opin Investig Drugs*. 2001;2:1375–7.
- [232]. Lin X *Cryptococcus neoformans*: Morphogenesis, infection, and evolution. *Infection, Genetics and Evolution*. 2009;9:401–16.
- [233]. Botts MR, Giles SS, Gates MA, Kozel TR, Hull CM. Isolation and characterization of *Cryptococcus neoformans* spores reveal a critical role for capsule biosynthesis genes in spore biogenesis. *Eukaryotic cell*. 2009;8:595–605. [PubMed: 19181873]
- [234]. Velagapudi R, Hsueh Y-P, Geunes-Boyer S, Wright JR, Heitman J. Spores as infectious propagules of *Cryptococcus neoformans*. *Infection and immunity*. 2009;77:4345–55. [PubMed: 19620339]
- [235]. Lin X, Litvintseva AP, Nielsen K, Patel S, Floyd A, Mitchell TG, et al. alpha AD alpha hybrids of *Cryptococcus neoformans*: evidence of same-sex mating in nature and hybrid fitness. *PLoS genetics*. 2007;3:1975–90. [PubMed: 17953489]
- [236]. Phadke SS, Feretzaki M, Clancey SA, Mueller O, Heitman J. Unisexual Reproduction of *Cryptococcus gattii*. *PLOS ONE*. 2014;9:e111089. [PubMed: 25337713]
- [237]. Nielsen K, Cox GM, Wang P, Toffaletti DL, Perfect JR, Heitman J. Sexual Cycle of *Cryptococcus neoformans* var. *grubii* and Virulence of Congenic α and α Isolates. *Infection and Immunity*. 2003;71:4831–41. [PubMed: 12933823]
- [238]. Bui T, Lin X, Malik R, Heitman J, Carter D. Isolates of *Cryptococcus neoformans* from infected animals reveal genetic exchange in unisexual, alpha mating type populations. *Eukaryotic cell*. 2008;7:1771–80. [PubMed: 18552280]
- [239]. Wang L, Lin X. Mechanisms of unisexual mating in *Cryptococcus neoformans*. *Fungal Genetics and Biology*. 2011;48:651–60. [PubMed: 21320625]
- [240]. Okagaki LH, Strain AK, Nielsen JN, Charlier C, Baltes NJ, Chrétien F, et al. Cryptococcal Cell Morphology Affects Host Cell Interactions and Pathogenicity. *PLOS Pathogens*. 2010;6:e1000953. [PubMed: 20585559]
- [241]. Zaragoza O, Garcia-Rodas R, Nosanchuk JD, Cuenca-Estrella M, Rodriguez-Tudela JL, Casadevall A. Fungal cell gigantism during mammalian infection. *PLoS Pathog*. 2010;6:e1000945. [PubMed: 20585557]
- [242]. O'Meara TR, Alspaugh JA. The *Cryptococcus neoformans* capsule: a sword and a shield. *Clinical microbiology reviews*. 2012;25:387–408. [PubMed: 22763631]
- [243]. Okagaki LH, Nielsen K. Titan Cells Confer Protection from Phagocytosis in *Cryptococcus neoformans* Infections. *Eukaryot Cell*. 2012;11:820–6. [PubMed: 22544904]
- [244]. Dambuzza IM, Drake T, Chapuis A, Zhou X, Correia J, Taylor-Smith L, et al. The *Cryptococcus neoformans* Titan cell is an inducible and regulated morphotype underlying pathogenesis. *PLOS Pathogens*. 2018;14:e1006978. [PubMed: 29775474]
- [245]. Hommel B, Mukaremera L, Cordero RJB, Coelho C, Desjardins CA, Sturny-Leclère A, et al. Titan cells formation in *Cryptococcus neoformans* is finely tuned by environmental conditions and modulated by positive and negative genetic regulators. *PLOS Pathogens*. 2018;14:e1006982. [PubMed: 29775480]
- [246]. Trevijano-Contador N, de Oliveira HC, García-Rodas R, Rossi SA, Llorente I, Zaballos Á, et al. *Cryptococcus neoformans* can form titan-like cells in vitro in response to multiple signals. *PLOS Pathogens*. 2018;14:e1007007. [PubMed: 29775477]
- [247]. Okagaki LH, Wang Y, Ballou ER, O'Meara TR, Bahn Y-S, Alspaugh JA, et al. Cryptococcal Titan Cell Formation Is Regulated by G-Protein Signaling in Response to Multiple Stimuli. 2011;10:1306–16.
- [248]. Davis D, Edwards JE Jr., Mitchell AP, Ibrahim AS. *Candida albicans* RIM101 pH response pathway is required for host-pathogen interactions. *Infection and immunity*. 2000;68:5953–9. [PubMed: 10992507]
- [249]. Zaragoza O, Nielsen K. Titan cells in *Cryptococcus neoformans*: cells with a giant impact. *Current opinion in microbiology*. 2013;16:409–13. [PubMed: 23588027]

- [250]. Holbrook ED, Edwards JA, Youseff BH, Rappleye CA. Definition of the Extracellular Proteome of Pathogenic-Phase *Histoplasma capsulatum*. *Journal of Proteome Research*. 2011;10:1929–43. [PubMed: 21291285]
- [251]. Gilmore SA, Voorhies M, Gebhart D, Sil A. Genome-Wide Reprogramming of Transcript Architecture by Temperature Specifies the Developmental States of the Human Pathogen *Histoplasma*. *PLOS Genetics*. 2015;11:e1005395. [PubMed: 26177267]
- [252]. Edwards JA, Chen C, Kemski MM, Hu J, Mitchell TK, Rappleye CA. *Histoplasma* yeast and mycelial transcriptomes reveal pathogenic-phase and lineage-specific gene expression profiles. *BMC Genomics*. 2013;14:695. [PubMed: 24112604]
- [253]. Maresca B, Lambowitz AM, Kumar VB, Grant GA, Kobayashi GS, Medoff G. Role of cysteine in regulating morphogenesis and mitochondrial activity in the dimorphic fungus *Histoplasma capsulatum*. *Proceedings of the National Academy of Sciences of the United States of America*. 1981;78:4596–600. [PubMed: 6945601]
- [254]. Medoff G, Painter A, Kobayashi GS. Mycelial- to yeast-phase transitions of the dimorphic fungi *Blastomyces dermatitidis* and *Paracoccidioides brasiliensis*. *Journal of bacteriology*. 1987;169:4055–60. [PubMed: 3624202]
- [255]. McBride JA, Gauthier GM, Klein BS. Turning on virulence: Mechanisms that underpin the morphologic transition and pathogenicity of *Blastomyces*. *Virulence*. 2018:1–9.
- [256]. Converse JL. Effect of physico-chemical environment of spherulation of *Coccidioides immitis* in a chemically defined medium. *Journal of bacteriology*. 1956;72:784–92. [PubMed: 13398364]
- [257]. Pine L. Studies on the growth of *Histoplasma capsulatum*. I. Growth of the yeast phase in liquid media. *Journal of bacteriology*. 1954;68:671–9. [PubMed: 13221542]
- [258]. Nguyen VQ, Sil A. Temperature-induced switch to the pathogenic yeast form of *Histoplasma capsulatum* requires Ryp1, a conserved transcriptional regulator. *Proc Natl Acad Sci U S A*. 2008;105:4880–5. [PubMed: 18339808]
- [259]. Webster RH, Sil A. Conserved factors Ryp2 and Ryp3 control cell morphology and infectious spore formation in the fungal pathogen *Histoplasma capsulatum*. *Proceedings of the National Academy of Sciences*. 2008;105:14573.
- [260]. Beyhan S, Gutierrez M, Voorhies M, Sil A. A Temperature-Responsive Network Links Cell Shape and Virulence Traits in a Primary Fungal Pathogen. *PLOS Biology*. 2013;11:e1001614. [PubMed: 23935449]
- [261]. Laskowski-Peak MC, Calvo AM, Rohrsen J, Smulian AG. VEA1 is required for cleistothecial formation and virulence in *Histoplasma capsulatum*. *Fungal Genet Biol*. 2012;49:838–46. [PubMed: 22841690]
- [262]. Nemecek JC, Wüthrich M, Klein BS. Global Control of Dimorphism and Virulence in Fungi. *Science*. 2006;312:583. [PubMed: 16645097]
- [263]. Lawry SM, Tebbets B, Kean I, Stewart D, Hetelle J, Klein BS. Fludioxonil Induces Drk1, a Fungal Group III Hybrid Histidine Kinase, To Dephosphorylate Its Downstream Target, Ypd1. *Antimicrob Agents Chemother*. 2017;61.
- [264]. Muñoz-Hernández B, Palma-Cortés G, Cabello-Gutiérrez C, Martínez-Rivera MA. Parasitic polymorphism of *Coccidioides* spp. *BMC Infectious Diseases*. 2014;14:213. [PubMed: 24750998]
- [265]. Whiston E, Zhang Wise H, Sharpton TJ, Jui G, Cole GT, Taylor JW. Comparative Transcriptomics of the Saprobic and Parasitic Growth Phases in *Coccidioides* spp. *PLOS ONE*. 2012;7:e41034. [PubMed: 22911737]
- [266]. Viriyakosol S, Singhanian A, Fierer J, Goldberg J, Kirkland TN, Woelk CH. Gene expression in human fungal pathogen *Coccidioides immitis* changes as arthroconidia differentiate into spherules and mature. *BMC Microbiology*. 2013;13:121. [PubMed: 23714098]
- [267]. Mitchell NM, Sherrard AL, Dasari S, Magee DM, Grys TE, Lake DF. Proteogenomic Re-Annotation of *Coccidioides posadasii* Strain Silveira. *Proteomics*. 2018;18.
- [268]. Erwig LP, Gow NAR. Interactions of fungal pathogens with phagocytes. *Nature Reviews Microbiology*. 2016;14:163. [PubMed: 26853116]

- [269]. Rosowski EE, Raffa N, Knox BP, Golenberg N, Keller NP, Huttenlocher A. Macrophages inhibit *Aspergillus fumigatus* germination and neutrophil-mediated fungal killing. *PLOS Pathogens*. 2018;14:e1007229. [PubMed: 30071103]
- [270]. Aimaniananda V, Bayry J, Bozza S, Knemeyer O, Perruccio K, Elluru SR, et al. Surface hydrophobin prevents immune recognition of airborne fungal spores. *Nature*. 2009;460:1117. [PubMed: 19713928]
- [271]. Gersuk GM, Underhill DM, Zhu L, Marr KA. Dectin-1 and TLRs Permit Macrophages to Distinguish between Different *Aspergillus fumigatus* Cellular States. *The Journal of Immunology*. 2006;176:3717–24. [PubMed: 16517740]
- [272]. Hohl TM, Van Epps HL, Rivera A, Morgan LA, Chen PL, Feldmesser M, et al. *Aspergillus fumigatus* Triggers Inflammatory Responses by Stage-Specific β -Glucan Display. *PLOS Pathog*. 2005;1:e30. [PubMed: 16304610]
- [273]. Brown GD, Gordon S. A new receptor for β -glucans. *Nature*. 2001;413:36.
- [274]. Luther K, Torosantucci A, Brakhage AA, Heesemann J, Ebel F. Phagocytosis of *Aspergillus fumigatus* conidia by murine macrophages involves recognition by the dectin-1 beta-glucan receptor and Toll-like receptor 2. *Cellular Microbiology*. 2007;9:368–81. [PubMed: 16953804]
- [275]. Balloy V, Sallenave J-M, Wu Y, Touqui L, Latgé J-P, Si-Tahar M, et al. *Aspergillus fumigatus*-induced interleukin-8 synthesis by respiratory epithelial cells is controlled by the phosphatidylinositol 3-kinase, p38 MAPK, and ERK1/2 pathways and not by the toll-like receptor-MyD88 pathway. *The Journal of biological chemistry*. 2008;283:30513–21. [PubMed: 18703508]
- [276]. Beauvais A, Schmidt C, Guadagnini S, Roux P, Perret E, Henry C, et al. An extracellular matrix glues together the aerial-grown hyphae of *Aspergillus fumigatus*. *Cellular Microbiology*. 2007;9:1588–600. [PubMed: 17371405]
- [277]. Bamford NC, Snarr BD, Gravelat FN, Little DJ, Lee MJ, Zacharias CA, et al. Sph3 Is a Glycoside Hydrolase Required for the Biosynthesis of Galactosaminogalactan in *Aspergillus fumigatus*. *The Journal of biological chemistry*. 2015;290:27438–50. [PubMed: 26342082]
- [278]. Loussert C, Schmitt C, Prevost M-C, Balloy V, Fadel E, Philippe B, et al. In vivo biofilm composition of *Aspergillus fumigatus*. *Cellular Microbiology*. 2010;12:405–10. [PubMed: 19889082]
- [279]. Takahashi H, Kusuya Y, Hagiwara D, Takahashi-Nakaguchi A, Sakai K, Gono T. Global gene expression reveals stress-responsive genes in *Aspergillus fumigatus* mycelia. *BMC genomics*. 2017;18:942-. [PubMed: 29202712]
- [280]. de Assis LJ, Manfioli A, Mattos E, Fabri JHTM, Malavazi I, Jacobsen ID, et al. Protein Kinase A and High-Osmolarity Glycerol Response Pathways Cooperatively Control Cell Wall Carbohydrate Mobilization in *Aspergillus fumigatus*. *mBio*. 2018;9:e01952–18. [PubMed: 30538182]
- [281]. Dhingra S, Kowlaski CH, Thammahong A, Beattie SR, Bultman KM, Cramer RA. RbdB, a Rhomboid Protease Critical for SREBP Activation and Virulence in *Aspergillus fumigatus*. *mSphere*. 2016;1:e00035–16. [PubMed: 27303716]
- [282]. Zaragoza O, Rodrigues ML, De Jesus M, Frases S, Dadachova E, Casadevall A. The capsule of the fungal pathogen *Cryptococcus neoformans*. *Advances in applied microbiology*. 2009;68:133–216. [PubMed: 19426855]
- [283]. Reese AJ, Yoneda A, Breger JA, Beauvais A, Liu H, Griffith CL, et al. Loss of cell wall alpha(1–3) glucan affects *Cryptococcus neoformans* from ultrastructure to virulence. *Molecular microbiology*. 2007;63:1385–98. [PubMed: 17244196]
- [284]. Vartivarian SE, Anaissie EJ, Cowart RE, Sprigg HA, Tingler MJ, Jacobson ES. Regulation of Cryptococcal Capsular Polysaccharide by Iron. *The Journal of Infectious Diseases*. 1993;167:186–90. [PubMed: 8418165]
- [285]. Granger DL, Perfect JR, Durack DT. Virulence of *Cryptococcus neoformans*. Regulation of capsule synthesis by carbon dioxide. *The Journal of Clinical Investigation*. 1985;76:508–16. [PubMed: 3928681]
- [286]. Zaragoza O, Casadevall A. Experimental modulation of capsule size in *Cryptococcus neoformans*. *Biol Proced Online*. 2004;6:10–5. [PubMed: 15103395]

- [287]. Ost KS, O'Meara TR, Huda N, Esher SK, Alspaugh JA. The *Cryptococcus neoformans* Alkaline Response Pathway: Identification of a Novel Rim Pathway Activator. *PLoS Genetics*. 2015;11:e1005159. [PubMed: 25859664]
- [288]. Pianalto KM, Ost KS, Brown HE, Alspaugh JA. Characterization of additional components of the environmental pH-sensing complex in the pathogenic fungus *Cryptococcus neoformans*. 2018;293:9995–10008.
- [289]. Ost KS, Esher SK, Leopold Wager CM, Walker L, Wagener J, Munro C, et al. Rim Pathway-Mediated Alterations in the Fungal Cell Wall Influence Immune Recognition and Inflammation. *MBio*. 2017;8.
- [290]. Chang YC, Kwon-Chung KJ. Isolation of the Third Capsule-Associated Gene, CAP60, Required for Virulence in *Cryptococcus neoformans*. *Infection and Immunity*. 1998;66:2230–6. [PubMed: 9573112]
- [291]. Chang YC, Cherniak R, Kozel TR, Granger DL, Morris LC, Weinhold LC, et al. Structure and biological activities of acapsular *Cryptococcus neoformans* 602 complemented with the CAP64 gene. *Infection and Immunity*. 1997;65:1584–92. [PubMed: 9125534]
- [292]. Mahajan KR, Roberts AL, Curtis MT, Fortuna D, Dharia R, Sheehan L. Diagnostic Challenges of *Cryptococcus neoformans* in an Immunocompetent Individual Masquerading as Chronic Hydrocephalus. *Case Reports in Neurological Medicine*. 2016;2016:7.
- [293]. McFadden DC, Casadevall A. Capsule and melanin synthesis in *Cryptococcus neoformans*. *Med Mycol*. 2001;39 Suppl 1:19–30. [PubMed: 11800266]
- [294]. Wang Y, Aisen P, Casadevall A. *Cryptococcus neoformans* melanin and virulence: mechanism of action. *Infection and immunity*. 1995;63:3131–6. [PubMed: 7622240]
- [295]. Doering TL, Nosanchuk JD, Roberts WK, Casadevall A. Melanin as a potential cryptococcal defence against microbicidal proteins. *Med Mycol*. 1999;37:175–81. [PubMed: 10421849]
- [296]. Guimaraes AJ, de Cerqueira MD, Nosanchuk JD. Surface architecture of *histoplasma capsulatum*. *Front Microbiol*. 2011;2:225. [PubMed: 22121356]
- [297]. Cordero RJ, Liedke SC, de SAGR, Martinez LR, Nimrichter L, Frases S, et al. Enhanced virulence of *Histoplasma capsulatum* through transfer and surface incorporation of glycans from *Cryptococcus neoformans* during co-infection. *Sci Rep*. 2016;6:21765. [PubMed: 26908077]
- [298]. Rappleye CA, Engle JT, Goldman WE. RNA interference in *Histoplasma capsulatum* demonstrates a role for α -(1,3)-glucan in virulence. *Molecular microbiology*. 2004;53:153–65. [PubMed: 15225311]
- [299]. Rappleye CA, Eissenberg LG, Goldman WE. *Histoplasma capsulatum* α -(1,3)-glucan blocks innate immune recognition by the β -glucan receptor. *Proceedings of the National Academy of Sciences*. 2007;104:1366.
- [300]. Garfoot AL, Dearing KL, VanSchoiack AD, Wysocki VH, Rappleye CA. Eng1 and Exg8 Are the Major β -Glucanases Secreted by the Fungal Pathogen *Histoplasma capsulatum*. *The Journal of biological chemistry*. 2017;292:4801–10. [PubMed: 28154008]
- [301]. Garfoot AL, Shen Q, Wüthrich M, Klein BS, Rappleye CA. The Eng1 β -Glucanase Enhances *Histoplasma* Virulence by Reducing β -Glucan Exposure. *mBio*. 2016;7:e01388–15. [PubMed: 27094334]
- [302]. Edwards JA, Alore EA, Rappleye CA. The yeast-phase virulence requirement for α -glucan synthase differs among *Histoplasma capsulatum* chemotypes. *Eukaryotic Cell*. 2011;10:87. [PubMed: 21037179]
- [303]. Mayfield JA, Rine J. The genetic basis of variation in susceptibility to infection with *Histoplasma capsulatum* in the mouse. *Genes Immun*. 2007;8:468–74. [PubMed: 17625601]
- [304]. Kanetsuna F, Carbonell LM. Cell wall composition of the yeastlike and mycelial forms of *Blastomyces dermatitidis*. *Journal of bacteriology*. 1971;106:946–8. [PubMed: 5557599]
- [305]. Koneti A, Linke MJ, Brummer E, Stevens DA. Evasion of Innate Immune Responses: Evidence for Mannose Binding Lectin Inhibition of Tumor Necrosis Factor Alpha Production by Macrophages in Response to *Blastomyces dermatitidis*. *Infection and Immunity*. 2008;76:994. [PubMed: 18070904]

- [306]. del Pilar Jiménez-A M, Viriyakosol S, Walls L, Datta SK, Kirkland T, Heinsbroek SEM, et al. Susceptibility to *Coccidioides* species in C57BL/6 mice is associated with expression of a truncated splice variant of Dectin-1 (Clec7a). *Genes Immun.* 2008;9:338. [PubMed: 18418396]
- [307]. Xue J, Chen X, Selby D, Hung C-Y, Yu J-J, Cole GT. A genetically engineered live attenuated vaccine of *Coccidioides posadasii* protects BALB/c mice against coccidioidomycosis. *Infection and immunity.* 2009;77:3196–208. [PubMed: 19487479]
- [308]. Paris S, Boisvieux-Ulrich E, Crestani B, Houcine O, Taramelli D, Lombardi L, et al. Internalization of *Aspergillus fumigatus* conidia by epithelial and endothelial cells. *Infection and immunity.* 1997;65:1510–4. [PubMed: 9119494]
- [309]. Espinosa V, Rivera A. First Line of Defense: Innate Cell-Mediated Control of Pulmonary Aspergillosis. *Frontiers in microbiology.* 2016;7:272-. [PubMed: 26973640]
- [310]. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to *Aspergillus*. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. *The Journal of clinical investigation.* 1982;69:617–31. [PubMed: 7037853]
- [311]. Lopes Bezerra LM, Filler SG. Interactions of *Aspergillus fumigatus* with endothelial cells: internalization, injury, and stimulation of tissue factor activity. *Blood.* 2004;103:2143–9. [PubMed: 14630829]
- [312]. Bhatia S, Fei M, Yarlagadda M, Qi Z, Akira S, Saijo S, et al. Rapid host defense against *Aspergillus fumigatus* involves alveolar macrophages with a predominance of alternatively activated phenotype. *PloS one.* 2011;6:e15943–e. [PubMed: 21246055]
- [313]. Schaffner A, Douglas H, Braude AI, Davis CE. Killing of *Aspergillus* spores depends on the anatomical source of the macrophage. *Infection and immunity.* 1983;42:1109–15. [PubMed: 6642661]
- [314]. Thywißen A, Heinekamp T, Dahse H-M, Schmalzer-Ripcke J, Nietzsche S, Zipfel PF, et al. Conidial Dihydroxynaphthalene Melanin of the Human Pathogenic Fungus *Aspergillus fumigatus* Interferes with the Host Endocytosis Pathway. *Frontiers in microbiology.* 2011;2:96-. [PubMed: 21747802]
- [315]. Schmidt H, Vlaic S, Krüger T, Schmidt F, Balkenhol J, Dandekar T, et al. Proteomics of *Aspergillus fumigatus* Conidia-containing Phagolysosomes Identifies Processes Governing Immune Evasion. *Molecular & Cellular Proteomics.* 2018;17:1084–96. [PubMed: 29507050]
- [316]. Bonnett CR, Cornish EJ, Harmsen AG, Burritt JB. Early neutrophil recruitment and aggregation in the murine lung inhibit germination of *Aspergillus fumigatus* Conidia. *Infection and immunity.* 2006;74:6528–39. [PubMed: 16920786]
- [317]. Gazendam RP, van Hamme JL, Tool ATJ, Hoogenboezem M, van den Berg JM, Prins JM, et al. Human Neutrophils Use Different Mechanisms To Kill *Aspergillus fumigatus* Conidia and Hyphae: Evidence from Phagocyte Defects. *The Journal of Immunology.* 2016;196:1272–83. [PubMed: 26718340]
- [318]. Knox BP, Deng Q, Rood M, Eickhoff JC, Keller NP, Huttenlocher A. Distinct innate immune phagocyte responses to *Aspergillus fumigatus* conidia and hyphae in zebrafish larvae. *Eukaryotic cell.* 2014;13:1266–77. [PubMed: 24879123]
- [319]. Braem SGE, Rooijackers SHM, van Kessel KPM, de Cock H, Wösten HAB, van Strijp JAG, et al. Effective Neutrophil Phagocytosis of *Aspergillus fumigatus* Is Mediated by Classical Pathway Complement Activation. *Journal of Innate Immunity.* 2015;7:364–74. [PubMed: 25676601]
- [320]. Ellett F, Jorgensen J, Frydman GH, Jones CN, Irimia D. Neutrophil Interactions Stimulate Evasive Hyphal Branching by *Aspergillus fumigatus*. *PLOS Pathogens.* 2017;13:e1006154. [PubMed: 28076396]
- [321]. Lee MJ, Liu H, Barker BM, Snarr BD, Gravelat FN, Al Abdallah Q, et al. The Fungal Exopolysaccharide Galactosaminogalactan Mediates Virulence by Enhancing Resistance to Neutrophil Extracellular Traps. *PLoS pathogens.* 2015;11:e1005187–e. [PubMed: 26492565]
- [322]. Feldmesser M, Kress Y, Novikoff P, Casadevall A. *Cryptococcus neoformans* is a facultative intracellular pathogen in murine pulmonary infection. *Infect Immun.* 2000;68:4225–37. [PubMed: 10858240]

- [323]. Bojarczuk A, Miller KA, Hotham R, Lewis A, Ogryzko NV, Kamuyango AA, et al. *Cryptococcus neoformans* Intracellular Proliferation and Capsule Size Determines Early Macrophage Control of Infection. *Scientific Reports*. 2016;6:21489. [PubMed: 26887656]
- [324]. Vecchiarelli A, Pericolini E, Elena G, Kenno S, Perito S, Cenci E, et al. Elucidating the immunological function of the *Cryptococcus neoformans* capsule. 2013;8:1107–16.
- [325]. Chang ZL, Netski D, Thorkildson P, Kozel TR. Binding and Internalization of Glucuronoxylomannan, the Major Capsular Polysaccharide of *Cryptococcus neoformans*, by Murine Peritoneal Macrophages. *Infection and Immunity*. 2006;74:144–51. [PubMed: 16368967]
- [326]. Tucker SC, Casadevall A. Replication of *Cryptococcus neoformans* in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. 2002;99:3165–70.
- [327]. Levitz SM, Nong SH, Seetoo KF, Harrison TS, Speizer RA, Simons ER. *Cryptococcus neoformans* resides in an acidic phagolysosome of human macrophages. *Infection and immunity*. 1999;67:885–90. [PubMed: 9916104]
- [328]. Davis MJ, Eastman AJ, Qiu Y, Gregorka B, Kozel TR, Osterholzer JJ, et al. *Cryptococcus neoformans* Induced Macrophage Lysosome Damage Crucially Contributes to Fungal Virulence. 2015:1402376.
- [329]. Nicola AM, Robertson EJ, Albuquerque P, Derengowski LdS, Casadevall A. Nonlytic Exocytosis of *Cryptococcus neoformans* from Macrophages Occurs In Vivo and Is Influenced by Phagosomal pH. *mBio*. 2011;2:e00167–11. [PubMed: 21828219]
- [330]. Gilbert AS, Seoane PI, Sephton-Clark P, Bojarczuk A, Hotham R, Giurisato E, et al. Vomocytosis of live pathogens from macrophages is regulated by the atypical MAP kinase ERK5. 2017;3:e1700898.
- [331]. Ma H, Croudace JE, Lammas DA, May RC. Expulsion of Live Pathogenic Yeast by Macrophages. *Current Biology*. 2006;16:2156–60. [PubMed: 17084701]
- [332]. Alvarez M, Casadevall A. Phagosome Extrusion and Host-Cell Survival after *Cryptococcus neoformans* Phagocytosis by Macrophages. *Current Biology*. 2006;16:2161–5. [PubMed: 17084702]
- [333]. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. An Innate Immune System Cell Is a Major Determinant of Species-Related Susceptibility Differences to Fungal Pneumonia. *The Journal of Immunology*. 2005;175:3244–51. [PubMed: 16116215]
- [334]. Syme RM, Bruno TF, Kozel TR, Mody CH. The capsule of *Cryptococcus neoformans* reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. *Infection and immunity*. 1999;67:4620–7. [PubMed: 10456908]
- [335]. Vecchiarelli A, Pietrella D, Dottorini M, Monari C, Retini C, Todisco T, et al. Encapsulation of *Cryptococcus neoformans* regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. *Clinical and experimental immunology*. 1994;98:217–23. [PubMed: 7955525]
- [336]. Newman SL, Bucher C, Rhodes J, Bullock WE. Phagocytosis of *Histoplasma capsulatum* yeasts and microconidia by human cultured macrophages and alveolar macrophages. Cellular cytoskeleton requirement for attachment and ingestion. *The Journal of Clinical Investigation*. 1990;85:223–30. [PubMed: 2104879]
- [337]. Deepe GS Jr., Gibbons RS, Smulian AG. *Histoplasma capsulatum* manifests preferential invasion of phagocytic subpopulations in murine lungs. *J Leukoc Biol*. 2008;84:669–78. [PubMed: 18577715]
- [338]. Goodwin RA, Loyd JE, Des Prez RM. Histoplasmosis in normal hosts. *Medicine (Baltimore)*. 1981;60:231–66. [PubMed: 7017339]
- [339]. Ray SC, Rappleye CA. Flying under the radar: *Histoplasma capsulatum* avoidance of innate immune recognition. *Semin Cell Dev Biol*. 2018.
- [340]. Long KH, Gomez FJ, Morris RE, Newman SL. Identification of Heat Shock Protein 60 as the Ligand on *Histoplasma capsulatum* That Mediates Binding to CD18 Receptors on Human Macrophages. *The Journal of Immunology*. 2003;170:487. [PubMed: 12496435]

- [341]. Gildea LA, Morris RE, Newman SL. Histoplasma capsulatum Yeasts Are Phagocytosed Via Very Late Antigen-5, Killed, and Processed for Antigen Presentation by Human Dendritic Cells. *The Journal of Immunology*. 2001;166:1049. [PubMed: 11145684]
- [342]. Newman SL, Gootee L, Bucher C, Bullock WE. Inhibition of intracellular growth of Histoplasma capsulatum yeast cells by cytokine-activated human monocytes and macrophages. *Infection and immunity*. 1991;59:737–41. [PubMed: 1898916]
- [343]. Shen Q, Rappleye CA. Differentiation of the fungus Histoplasma capsulatum into a pathogen of phagocytes. *Curr Opin Microbiol*. 2017;40:1–7. [PubMed: 29096192]
- [344]. Garfoot AL, Rappleye CA. Histoplasma capsulatum surmounts obstacles to intracellular pathogenesis. *The FEBS Journal*. 2016;283:619–33. [PubMed: 26235362]
- [345]. Isaac DT, Berkes CA, English BC, Hocking Murray D, Lee YN, Coady A, et al. Macrophage cell death and transcriptional response are actively triggered by the fungal virulence factor Cbp1 during H. capsulatum infection. *Molecular Microbiology*. 2015;98:910–29. [PubMed: 26288377]
- [346]. Beck MR, DeKoster GT, Hambly DM, Gross ML, Cistola DP, Goldman WE. Structural Features Responsible for the Biological Stability of Histoplasma's Virulence Factor CBP. *Biochemistry*. 2008;47:4427–38. [PubMed: 18361504]
- [347]. Wise HZ, Hung C-Y, Whiston E, Taylor JW, Cole GT. Extracellular ammonia at sites of pulmonary infection with Coccidioides posadasii contributes to severity of the respiratory disease. *Microbial pathogenesis*. 2013;59–60:19–28.
- [348]. Castro-Lopez N, Hung C-Y. Immune Response to Coccidioidomycosis and the Development of a Vaccine. 2017;5:13.
- [349]. Sterkel AK, Mettelman R, Wüthrich M, Klein BS. The Unappreciated Intracellular Lifestyle of Blastomyces dermatitidis. 2015;194:1796–805.
- [350]. Williams JE, Moser SA, Turner SH, Standard PG. Development of pulmonary infection in mice inoculated with Blastomyces dermatitidis conidia. *American Journal of Respiratory and Critical Care Medicine*. 1994;149:500–9. [PubMed: 8306053]
- [351]. Sugar AM, Picard M, Wagner R, Kornfeld H. Interactions between Human Bronchoalveolar Macrophages and Blastomyces dermatitidis Conidia: Demonstration of Fungicidal and Fungistatic Effects. *The Journal of Infectious Diseases*. 1995;171:1559–62. [PubMed: 7769292]
- [352]. Drutz DJ, Frey CL. Intracellular and extracellular defenses of human phagocytes against Blastomyces dermatitidis conidia and yeasts. *The Journal of laboratory and clinical medicine*. 1985;105:737–50. [PubMed: 3998623]
- [353]. Rocco NM, Carmen JC, Klein BS. Blastomyces dermatitidis Yeast Cells Inhibit Nitric Oxide Production by Alveolar Macrophage Inducible Nitric Oxide Synthase. 2011;79:2385–95.
- [354]. SUGAR AM, BRUMMER E, STEVENS DA. Fungicidal activity of murine broncho-alveolar macrophages against Blastomyces dermatitidis. 1986;21:7–11.
- [355]. Bradsher RW, Ulmer WC, Marmer DJ, Townsend JW, Jacobs RF. Intracellular Growth and Phagocytosis of Blastomyces dermatitidis by Monocyte-Derived Macrophages from Previously Infected and Normal Subjects. *The Journal of Infectious Diseases*. 1985;151:57–64. [PubMed: 3965594]
- [356]. Brummer E, Vinoda V, Stevens DA. IL-12 induction of resistance to pulmonary blastomycosis. *Cytokine*. 2006;35:221–8. [PubMed: 17067810]
- [357]. Brummer E, Kethineni N, Stevens DA. Immunological basis for susceptibility and resistance to pulmonary blastomycosis in mouse strains. *Cytokine*. 2005;32:12–9. [PubMed: 16183299]
- [358]. Brummer E, Hanson LH, Stevens DA. IL-4, IgE, and Interferon- γ Production in Pulmonary Blastomycosis: Comparison in Mice Untreated, Immunized, or Treated with an Antifungal (SCH 39304). *Cellular Immunology*. 1993;149:258–67. [PubMed: 7687197]
- [359]. Hung C-Y, Yu J-J, Seshan KR, Reichard U, Cole GT. A Parasitic Phase-Specific Adhesin of Coccidioides immitis Contributes to the Virulence of This Respiratory Fungal Pathogen. *Infection and Immunity*. 2002;70:3443–56. [PubMed: 12065484]
- [360]. Hung CY, Ampel NM, Christian L, Seshan KR, Cole GT. A major cell surface antigen of Coccidioides immitis which elicits both humoral and cellular immune responses. *Infection and immunity*. 2000;68:584–93. [PubMed: 10639421]

- [361]. Hung C-Y, Seshan KR, Yu J-J, Schaller R, Xue J, Basrur V, et al. A Metalloproteinase of *Coccidioides posadasii* Contributes to Evasion of Host Detection. *Infection and Immunity*. 2005;73:6689–703. [PubMed: 16177346]
- [362]. Beaman L, Benjamini E, Pappagianis D. Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of *Coccidioides immitis*. *Infection and immunity*. 1983;39:1201–7. [PubMed: 6601622]
- [363]. Beaman L, Holmberg CA. In vitro response of alveolar macrophages to infection with *Coccidioides immitis*. *Infection and immunity*. 1980;28:594–600. [PubMed: 6772563]
- [364]. Gonzalez A, Hung C-Y, Cole GT. *Coccidioides* releases a soluble factor that suppresses nitric oxide production by murine primary macrophages. *Microbial pathogenesis*. 2011;50:100–8. [PubMed: 21129481]
- [365]. Gonzalez A, Hung C-Y, Cole GT. Nitric oxide synthase activity has limited influence on the control of *Coccidioides* infection in mice. *Microbial Pathogenesis*. 2011;51:161–8. [PubMed: 21513788]
- [366]. Margolis DA, Viriyakosol S, Fierer J, Kirkland TNJBM. The role of reactive oxygen intermediates in experimental coccidioidomycosis in mice. 2011;11:71.
- [367]. Shang Y, Xiao G, Zheng P, Cen K, Zhan S, Wang C. Divergent and Convergent Evolution of Fungal Pathogenicity. *Genome Biology and Evolution*. 2016;8:1374–87. [PubMed: 27071652]
- [368]. Jahn B, Koch A, Schmidt A, Wanner G, Gehringer H, Bhakdi S, et al. Isolation and characterization of a pigmentless-conidium mutant of *Aspergillus fumigatus* with altered conidial surface and reduced virulence. *Infection and immunity*. 1997;65:5110–7. [PubMed: 9393803]
- [369]. Langfelder K, Jahn B, Gehringer H, Schmidt A, Wanner G, Brakhage AA. Identification of a polyketide synthase gene (pksP) of *Aspergillus fumigatus* involved in conidial pigment biosynthesis and virulence. *Med Microbiol Immunol*. 1998;187:79–89. [PubMed: 9832321]
- [370]. Dagenais TRT, Keller NP. Pathogenesis of *Aspergillus fumigatus* in Invasive Aspergillosis. *Clinical microbiology reviews*. 2009;22:447–65. [PubMed: 19597008]
- [371]. Iadarola P, Lungarella G, Martorana PA, Viglio S, Guglielminetti M, Korzus E, et al. Lung injury and degradation of extracellular matrix components by *Aspergillus fumigatus* serine proteinase. *Exp Lung Res*. 1998;24:233–51.
- [372]. Bromley IM, Donaldson K. Binding of *Aspergillus fumigatus* spores to lung epithelial cells and basement membrane proteins: relevance to the asthmatic lung. *Thorax*. 1996;51:1203–9. [PubMed: 8994516]
- [373]. Bouchara JP, Sanchez M, Chevailler A, Marot-Leblond A, Lissitzky JC, Tronchin G, et al. Sialic acid-dependent recognition of laminin and fibrinogen by *Aspergillus fumigatus* conidia. *Infection and immunity*. 1997;65:2717–24. [PubMed: 9199441]
- [374]. Wasylnka JA, Simmer MI, Moore MM. Differences in sialic acid density in pathogenic and non-pathogenic *Aspergillus* species. *Microbiology*. 2001;147:869–77. [PubMed: 11283283]
- [375]. Dasari P, Shopova IA, Stroe M, Wartenberg D, Martin-Dahse H, Beyersdorf N, et al. AspF2 From *Aspergillus fumigatus* Recruits Human Immune Regulators for Immune Evasion and Cell Damage. *Front immunol*. 2018;9:1635-. [PubMed: 30166981]
- [376]. Behnsen J, Lessing F, Schindler S, Wartenberg D, Jacobsen ID, Thoen M, et al. Secreted *Aspergillus fumigatus* protease Alp1 degrades human complement proteins C3, C4, and C5. *Infection and immunity*. 2010;78:3585–94. [PubMed: 20498262]
- [377]. Richie DL, Hartl L, Amanianda V, Winters MS, Fuller KK, Miley MD, et al. A role for the unfolded protein response (UPR) in virulence and antifungal susceptibility in *Aspergillus fumigatus*. *PLoS pathogens*. 2009;5:e1000258–e. [PubMed: 19132084]
- [378]. Kothary MH, Chase T Jr., Macmillan JD. Correlation of elastase production by some strains of *Aspergillus fumigatus* with ability to cause pulmonary invasive aspergillosis in mice. *Infection and immunity*. 1984;43:320–5. [PubMed: 6360904]
- [379]. Blanco JL, Hontecillas R, Bouza E, Blanco I, Pelaez T, Muñoz P, et al. Correlation between the elastase activity index and invasiveness of clinical isolates of *Aspergillus fumigatus*. *Journal of clinical microbiology*. 2002;40:1811–3. [PubMed: 11980964]

- [380]. Feder V, Kmetzsch L, Staats CC, Vidal-Figueiredo N, Ligabue-Braun R, Carlini CR, et al. *Cryptococcus gattii* urease as a virulence factor and the relevance of enzymatic activity in cryptococcosis pathogenesis. *Febs j.* 2015;282:1406–18. [PubMed: 25675897]
- [381]. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. Urease as a virulence factor in experimental cryptococcosis. *Infect Immun.* 2000;68:443–8. [PubMed: 10639402]
- [382]. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen G-H, Sonstein J, et al. Cryptococcal Urease Promotes the Accumulation of Immature Dendritic Cells and a Non-Protective T2 Immune Response within the Lung. *The American Journal of Pathology.* 2009;174:932–43. [PubMed: 19218345]
- [383]. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, et al. Real-time imaging of trapping and urease-dependent transmigration of *Cryptococcus neoformans* in mouse brain. *The Journal of Clinical Investigation.* 2010;120:1683–93. [PubMed: 20424328]
- [384]. Cox GM, McDade HC, Chen SC, Tucker SC, Gottfredsson M, Wright LC, et al. Extracellular phospholipase activity is a virulence factor for *Cryptococcus neoformans*. *Mol Microbiol.* 2001;39:166–75. [PubMed: 11123698]
- [385]. Djordjevic J Role of Phospholipases in Fungal Fitness, Pathogenicity, and Drug Development – Lessons from *Cryptococcus Neoformans*. 2010;1.
- [386]. Ganendren R, Carter E, Sorrell T, Widmer F, Wright L. Phospholipase B activity enhances adhesion of *Cryptococcus neoformans* to a human lung epithelial cell line. *Microbes and infection.* 2006;8:1006–15. [PubMed: 16487740]
- [387]. Wright LC, Santangelo RM, Ganendren R, Payne J, Djordjevic JT, Sorrell TC. Cryptococcal Lipid Metabolism: Phospholipase B1 Is Implicated in Transcellular Metabolism of Macrophage-Derived Lipids. 2007;6:37–47.
- [388]. Evans RJ, Li Z, Hughes WS, Djordjevic JT, Nielsen K, May RC. Cryptococcal Phospholipase B1 Is Required for Intracellular Proliferation and Control of Titan Cell Morphology during Macrophage Infection. 2015;83:1296–304.
- [389]. Siafakas AR, Sorrell TC, Wright LC, Wilson C, Larsen M, Boadle R, et al. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. *J Biol Chem.* 2007;282:37508–14. [PubMed: 17947228]
- [390]. Chayakulkeeree M, Johnston SA, Oei JB, Lev S, Williamson PR, Wilson CF, et al. SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of *Cryptococcus neoformans*. 2011;80:1088–101.
- [391]. Vu K, Tham R, Uhrig JP, Thompson GR, Na Pombejra S, Jamklang M, et al. Invasion of the Central Nervous System by *Cryptococcus neoformans* Requires a Secreted Fungal Metalloprotease. *mBio.* 2014;5:e01101–14. [PubMed: 24895304]
- [392]. Na Pombejra S, Jamklang M, Uhrig JP, Vu K, Gelli A. The structure-function analysis of the Mpr1 metalloprotease determinants of activity during migration of fungal cells across the blood-brain barrier. *PLOS ONE.* 2018;13:e0203020. [PubMed: 30161190]
- [393]. Na Pombejra S, Salemi M, Phinney BS, Gelli A. The Metalloprotease, Mpr1, Engages AnnexinA2 to Promote the Transcytosis of Fungal Cells across the Blood-Brain Barrier. 2017;7.
- [394]. Aaron PA, Jamklang M, Uhrig JP, Gelli A. The blood–brain barrier internalises *Cryptococcus neoformans* via the EphA2-tyrosine kinase receptor. *Cellular Microbiology.* 2018;20:e12811.
- [395]. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. *Clin Infect Dis.* 2011;53:1019–23. [PubMed: 21940419]
- [396]. Robertson EJ, Najjuka G, Rolfes MA, Akampurira A, Jain N, Anantharanjit J, et al. *Cryptococcus neoformans* Ex Vivo Capsule Size Is Associated With Intracranial Pressure and Host Immune Response in HIV-associated Cryptococcal Meningitis. *The Journal of Infectious Diseases.* 2014;209:74–82. [PubMed: 23945372]
- [397]. Chiapello L, Iribarren P, Cervi L, Rubinstein H, Masih DT. Mechanisms for induction of immunosuppression during experimental cryptococcosis: role of glucuronoxylomannan. *Clin Immunol.* 2001;100:96–106. [PubMed: 11414750]

- [398]. Yauch LE, Lam JS, Levitz SM. Direct Inhibition of T-Cell Responses by the *Cryptococcus* Capsular Polysaccharide Glucuronoxylomannan. *PLOS Pathogens*. 2006;2:e120. [PubMed: 17096589]
- [399]. Monari C, Pericolini E, Bistoni G, Casadevall A, Kozel TR, Vecchiarelli A. *Cryptococcus neoformans* Capsular Glucuronoxylomannan Induces Expression of Fas Ligand in Macrophages. 2005;174:3461–8.
- [400]. Dong ZM, Murphy JW. Cryptococcal polysaccharides induce L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. *The Journal of Clinical Investigation*. 1996;97:689–98. [PubMed: 8609224]
- [401]. Lipovsky MM, Tsenova L, Coenjaerts FEJ, Kaplan G, Cherniak R, Hoepelman AIM. Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood–brain barrier in an animal model of acute bacterial meningitis. *Journal of Neuroimmunology*. 2000;111:10–4. [PubMed: 11063816]
- [402]. Denham ST, Verma S, Reynolds RC, Worne CL, Daugherty JM, Lane TE, et al. Regulated release of cryptococcal polysaccharide drives virulence and suppresses immune infiltration into the central nervous system. *Infect Immun*. 2017.
- [403]. Youseff BH, Holbrook ED, Smolnycki KA, Rappleye CA. Extracellular Superoxide Dismutase Protects *Histoplasma* Yeast Cells from Host-Derived Oxidative Stress. *PLOS Pathogens*. 2012;8:e1002713. [PubMed: 22615571]
- [404]. Holbrook ED, Smolnycki KA, Youseff BH, Rappleye CA. Redundant Catalases Detoxify Phagocyte Reactive Oxygen and Facilitate *Histoplasma capsulatum* Pathogenesis. *Infection and Immunity*. 2013;81:2334. [PubMed: 23589579]
- [405]. Muñoz JF, Gauthier GM, Desjardins CA, Gallo JE, Holder J, Sullivan TD, et al. The Dynamic Genome and Transcriptome of the Human Fungal Pathogen *Blastomyces* and Close Relative *Emmonsia*. *PLOS Genetics*. 2015;11:e1005493. [PubMed: 26439490]
- [406]. Brandhorst T, Wüthrich M, Finkel-Jimenez B, Klein B. A C-terminal EGF-like domain governs BAD1 localization to the yeast surface and fungal adherence to phagocytes, but is dispensable in immune modulation and pathogenicity of *Blastomyces dermatitidis*. *Molecular Microbiology*. 2003;48:53–65. [PubMed: 12657044]
- [407]. Brandhorst TT, Roy R, Wüthrich M, Nanjappa S, Filutowicz H, Galles K, et al. Structure and Function of a Fungal Adhesin that Binds Heparin and Mimics Thrombospondin-1 by Blocking T Cell Activation and Effector Function. *PLOS Pathogens*. 2013;9:e1003464. [PubMed: 23853587]
- [408]. Beaussart A, Brandhorst T, Dufrêne YF, Klein BS. *Blastomyces* Virulence Adhesin-1 Protein Binding to Glycosaminoglycans Is Enhanced by Protein Disulfide Isomerase. *mBio*. 2015;6:e01403–15. [PubMed: 26396244]
- [409]. Finkel-Jimenez B, Wüthrich M, Klein BS. BAD1, an Essential Virulence Factor of *Blastomyces dermatitidis* Suppresses Host TNF- α Production Through TGF- β -Dependent and -Independent Mechanisms. *The Journal of Immunology*. 2002;168:5746. [PubMed: 12023375]
- [410]. Brandhorst TT, Wüthrich M, Finkel-Jimenez B, Warner T, Klein BS. Exploiting Type 3 Complement Receptor for TNF- α Suppression, Immune Evasion, and Progressive Pulmonary Fungal Infection. *The Journal of Immunology*. 2004;173:7444. [PubMed: 15585870]
- [411]. Sterkel AK, Lorenzini JL, Fites JS, Subramanian Vignesh K, Sullivan TD, Wüthrich M, et al. Fungal Mimicry of a Mammalian Aminopeptidase Disables Innate Immunity and Promotes Pathogenicity. *Cell Host Microbe*. 2016;19:361–74. [PubMed: 26922990]
- [412]. Mirbod-Donovan F, Schaller R, Hung C-Y, Xue J, Reichard U, Cole GT. Urease produced by *Coccidioides posadasii* contributes to the virulence of this respiratory pathogen. *Infection and immunity*. 2006;74:504–15. [PubMed: 16369007]
- [413]. Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E, Casadevall A. Phospholipids Trigger *Cryptococcus neoformans* Capsular Enlargement during Interactions with Amoebae and Macrophages. *PLOS Pathogens*. 2011;7:e1002047. [PubMed: 21637814]
- [414]. Taylor ML, Chávez-Tapia CB, Vargas-Yañez R, Rodríguez-Arellanes G, Peña-Sandoval GR, Toriello C, et al. Environmental conditions favoring bat infection with *Histoplasma capsulatum* in Mexican shelters. *Am J Trop Med Hyg*. 1999;61:914–9. [PubMed: 10674670]

- [415]. Taylor JW, Barker BM. The endozoan, small-mammal reservoir hypothesis and the life cycle of *Coccidioides* species. *Medical Mycology*. 2019;57:S16–S20. [PubMed: 30690603]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

- Exposure to environmental fungi is frequent and universal
- Environmental fungi cause a range of outcomes, from asymptomatic infections to severe systemic disease
- Fungi must adapt to different conditions in the environment and the host and the selective pressures conferred by the former facilitate the latter

Table 1:

Opportunistic fungi and risk factors for life-threatening infection.

Fungi	Natural Niche	Severe Clinical Outcomes	Risk Factors for life-threatening infections	Estimated lifethreatening infections/year
<i>Aspergillus</i>	• Globally distributed	• Invasive pulmonary aspergillosis (IPA)	• Neutropenia	>200,000 globally [4]
		• Chronic pulmonary aspergillosis (CPA)	• Bone marrow transplants	
		• Allergic bronchopulmonary aspergillosis (ABPA)	• Diabetes mellitus	
			• Corticosteroids	
			• COPD	
			• Cystic fibrosis	
			• HIV/AIDS	>200,000 globally [8]
			• CD4+ Lymphopenia	
			• TNF inhibitors	
			• Sarcoidosis	
			• Renal failure	
			• Chronic liver disease	
			• Diabetes	
			• Long-term steroid use	
			• Solid Organ Transplants	
			• Chemotherapy-induced immunosuppression	
			• TNF- α inhibitors	
			• Anti GM-CSF antibodies	
			• Anti IFN- γ antibodies	
			• Antibody deficiency	
			• IgG2 deficiency	
			• Fc γ receptor IIB variants	
			• Mannose-binding lectin deficiencies	
			• IL-12 receptor deficiency	
			• HIV/AIDS	~25,000 in the United States [4]
			• Organ/bone marrow transplants	
			• TNF- α inhibitors	
			• COPD	
			• Smoking	
<i>Histoplasma</i>	• Ohio and Mississippi river valleys of North America	Histoplasmosis		
	• South and Central America			
	• Sub-Saharan Africa			

Fungi	Natural Niche	Severe Clinical Outcomes	Risk Factors for life-threatening infections	Estimated lifethreatening infections/year
<i>Blastomyces</i>	<ul style="list-style-type: none"> Humid or semi-humid river basins Associated with bird or bat guano 	Acute respiratory distress syndrome (ARDS)	<ul style="list-style-type: none"> Extreme young or old MHC haplotypes IFN-γ receptor 1 deficiency 	~3,000 in the United States [4]
	<ul style="list-style-type: none"> Ohio and Mississippi river valleys Great Lakes region St. Lawrence river of Canada and North America Some in Africa and India Fresh water drainage basins Forested areas near lakes and rivers 		<ul style="list-style-type: none"> HIV/AIDS TNF-α inhibitors Solid Organ Transplants 	
			<ul style="list-style-type: none"> HIV/AIDS Solid Organ Transplants TNF-α inhibitors Extreme age Diabetes Pregnancy African and Filipino ethnicities IFN-γ receptor 1 gene function or deletion (<i>IFNGR1</i> 818del14) SNP in IL-12 Receptor gene (IL12RB1 C186Y) Gain of function mutations STAT1 	
	<ul style="list-style-type: none"> Southwest United States Northern Mexico Central Valley of California Arid desert climates 			
<i>Coccidioides</i>		Pneumonia (Valley Fever)		~25,000 in the United States [4]

Opportunistic fungi with corresponding geographical range. Summary of host risk factors that contribute to severe disease and estimated amount of life-threatening infections [4, 8]. TNF (Tumor necrosis factor); COPD (Chronic obstructive pulmonary disease). All other references in text.